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SUMMARY
Nitric oxide (NO) is a highly reactive molecule with physiological and 
pathological roles in the aii*ways. This thesis first investigated the production of 
NO in the airways of cystic fibrosis patients compared to normal and astlimatic 
subjects after validating a method to measure this which excluded known 
confoimding factors. The first finding was that exhaled NO, against expectation 
were not increased in cystic fibrosis patients, even during infective exacerbations. 
I hypothesised that this could be due to lack of detection o f NO (secondary to 
removal of NO by reaction with other reactive molecules and/or impedance of 
diffusion o f this gaseous molecule into the airway) or lack o f production 
(secondary to decreased expression of nitric oxide synthase II (NOS II), the gene 
thought to be responsible for NO production within an inflammatory setting). The 
thesis thus explored these possibilities by investigating a) exhaled NO levels in 
patients with bronchiectasis, a gi'oup of patients with similar suppm'ative aii*way 
disease to cystic fibrosis b) breath condensate levels of hydrogen peroxide, 
another highly reactive volatile molecule in cystic fibrosis patients compared to 
nornial subjects c) expression of NOS II in cystic fibrosis and noimal primaiy 
epithelial cells and epithelial cell lines at baseline and in response to 
proinflammatory stimuli and d) nitrite levels in breath condensate of CF patients. 
In order to perforai the above, methods for measuring hydrogen peroxide and 
nitrite in breath condensate were developed. The coiTelation between the levels of
these molecules and lung function and circulating leucocytes were also 
determined.
The thesis found that like exhaled gaseous NO, hydrogen peroxide levels were not 
elevated in exhaled air o f patients with CF. However nitrite levels were increased
.and this conelated with the levels of circulating leucocytes. The expression of 
NOS II were normal in primary cystic fibrosis epithelial cells and epithelial cell 
lines in vitro. Therefore, it is concluded that exhaled NO is not helpful as a marker 
of airways inflammation in chronic suppurative airway diseases o f cystic fibrosis
and bronchiectasis. This is likely to be due to lack of detection rather than ■‘.r
" 'Iproduction o f NO from the epithelium. Breath condensate nitrite levels may be a 
more useful tool for measuring airways inflammation in these conditions and 
further developments in this area are suggested.
ABBREVIATION
AAV Adeno-associated vims
AP1 activator protein 1
AP2 activator protein 2
ARDS adult respiratory distress syndrome
BAL bronchoalveolar lavage
Bcl-2 B cell lymphoma-2
cAMP adenosine 3’, 5’ - cyclic monophosphate
CD cluster of differentiation
CF cystic fibrosis
CFTE cystic fibrosis tracheal epithelium
CFTR cystic fibrosis transmembrane conductance regulator
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COPD clironic obstmctive pulmonary disease
COX cyclo-oxygenase
CREB/ATF cAMP response element binding protein/activating transcription 
factor
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CHAPTER 1 
INTRODUCTION
1,1 ENDOGENOUS NITRIC OXIDE AND ITS DISCOVERY
In 1980, Furchgott and Zawadzki showed that the endothelium was essential for 
the vasodilator action o f acetylcholine in isolated arterial strips (Fui'chgott RF, 
1980). Removal of the endothelium prevented the relaxant effect o f acetyl choline 
and even led to contraction o f the artery while stimulation of the endothelial cells 
caused the release of a substance, which Furchgott named endothelium derived 
relaxing factor (EDRF). Many other endogenous vasoactive substances including 
bradykinin, histamine, adenine nucleotides, thrombin, substance F and 5- 
hydroxytryptamine were found to act through the release of EDRF (Furchgott RF, 
1989. Ignarro LJ, 1989. Moncada S, 1993).
14
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The first indication that the body produces nitrate endogenously came in 1916
I
when dietary balance studies showed that more nitrate was excreted than was
ingested (Mitchell HH, 1916). This excess was thought to be produced by
microorganisms and it was not until Tamienbaum and his colleagues proved that 
.nitrate was biosynthesised mainly outside the intestine (Green LC, 1981) that 
interest in this area was renewed. Urinaiy nitrate levels in rats could be increased 
ten fold with injection of bacterial toxins and immunostimulated macrophages 
were found to produce high amounts o f nitrite and nitrate (Ivengar R, 1987).
The chemical nature of EDRF was not discovered until 1987 when Furchgott and
Ignarro independently pointed out that EDRF and NO were very similar in their 
biological properties. Soon afterwards, Moncada and colleagues compared the 
release and bioactivity of NO and EDRF in endothelial cell culture and foimd that 
EDRF was indistinguishable from NO (Palmer RMJ, 1987). Since then there has
Murad (but not Moncada, perhaps unjustly) were awarded the Nobel prize in 
Physiology and Medicine for their contribution to its discovery.
been an explosion of research on NO and its effects. It has heen difficult to 
believe that such a simple molecule should turn out to affect almost every 
function in the body and have such far reaching consequences. In 1992, Science 
picked NO as the ‘Molecule of the Year’ and in 1998, Furchgott, Ignarro and
15
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1.2 THE CHEMISTRY OF NITRIC OXIDE
Nitrogen oxides of biological relevance include elemental nitrogen in five 
oxidation states (+1 to +5) (table 1). Nitroxyl anion (NO ) and the product of its 
protonation, dimerization and dehydration, NgO, contains nitrogen in the + 1
■
oxidation state. The nitric oxide free radical (NO ) contains nitrogen in the +2 
.oxidation state. There are four important oxides in the +3 states: the weak base, 
nitrite (NO^ ) and the corresponding acid, nitrous acid or HNO 2  ; the nitrosonium 
cation (NO^), dinitrogen trioxide (N2 O3 ) and the peroxynitrite anion (ONOO ).
Nitrogen dioxide radical (NOg.) and its dimer, dinitrogen tetroxide (NgOJ, with 
which it is in equilibrium, contain nitrogen in the +4 oxidation state. Finally, in 
nitrate (NO^ ), its corresponding acid (HNO3, nitric acid), and dinitrogen 
pentoxide (N2 O5 ), nitrogen is in the +5 oxidation state.
In part as a consequence of the multiple oxidation states available for nitrogen,
NO does not to persist as the NO moiety for any length o f time in biological
settings. Rather it is oxidised, reduced or complexed with other biomolecules
depending on the conditions that prevail in its micr0 environment. These
alterations in the molecular form of NO have three distinct effects; firstly they can
modify the reactivity of NO so that it can be shuttled from its site o f production to
.its site of effect. Secondly, local reactions may enhance or inhibit the toxicity of 
NO , and thirdly, as a consequence of the reaction of NO with certain cairier
16
Redox reactions in the presence of oxygen
HNO^^NO^ +H+ 
HNO3 #  NO3- +
NO +N 02^N203  
N2O3 + H2O —> 2HNO2
H N O ,# N O /+ H +
NO + XFe"^ [X-Fe’^ -NO.] ^ X F e ' ^-NO" 
NO + YFe" f  [Y- Fe" -NO.] #  YFe'^hNO'
Reaction of NO with superoxide
Table l.K ey chemical reactions of nitric oxide.
Î
i
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2N0- + 0 2 f  2 NO2 
2 NO2
N ,0 , + H ,0 -> HNO, + HNO,
Interconversion among the NO redox airay in the 
presence of transition metals
.1
NO + O 2  OONO- e  OONOH #  NO 2  ....OH
—
molecules, the activity of the carrier molecules may be modified so as to change 
their bio activity reversibly.
Four chemical reactions are particularly pertinent biologically:
1. Redox reactions in the presence of oxygen.
In oxygenated aqueous and gaseous enviromnents (e.g. air/fluid interface in the 
airways), rapid interconversion among NO species may occur as shown in table 1 
(Marietta MA, 1990. Marietta MA, 1988. Gillespie R, 1989).
Thus, NO generation in aqueous biological systems and at air-aqueous interfaces 
is marked by the formation o f end products o f NO metabolism, NO^' and NO^ 
(Stamler JS, 1992a). N0^‘ is widely believed to be the major end product of the 
reaction between NO and Oj in aqueous solutions; however, much of the aqueous 
chemistry in biological systems remains poorly understood (Gaston B, 1994). 
Acidic conditions such as those that may be found in the airway are likely to alter 
the distribution of NO species in aqueous solution, largely as a result of 
decomposition of NO^" to the reactive NO^ equivalent, N 2 O3  (Marietta MA, 1988). 
Transition metal and related redox enzymes may also support the oxidation of 
NO^ to NO^", to account for the latter’s prevalence in cellular system.
2. Reaction of NO with transition metals.
NO readily reacts with transition metal ions free in solution and with both haem 
and non haem metalloproteins (Stamler JS, 1992a. Wan Q, 1991). The interaction
...
i
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between NO and iron is biologically important because it forms the basis for the 
action o f NO in at least four physiological systems -
i. guanylyl cyclase activation, inducing a stereochemical change within the 
porphyrin ring o f the enzyme (Wong SK 1992).
ii. the inhibitory action o f haemoglobin in systems in which NO is generated or 
administered
iii. nitrosylation o f iron-sulfiir centered proteins in macrophage driven cidal 
reactions (Hibbs JB, 1988. Hibbs JB, 1987.)
iv.modification of function of metalloproteins like cytochrome c, myoglobin and 
tyrosinase (Henry Y, 1991).
3. Nitrosation o f nitrogen and sulfur containing compounds.
The nitrosation of biologically relevant nucleophilic centres (N,S,C and O) 
involves the transfer o f NO'*' in the form of N^Og, N 2 O4 , iron nitrosyls, 
nitrososamines (RNH-NO) and S-nitrosothiol (RS-NO). Under normal 
physiological conditions, thiols are more reactive than amines and S-nitrosation
occurs preferentially over N-nitrosation (Stamler JS, 1992a).
The formation o f RS-NO derivatives may be viewed as a means of stabilising NO 
in the bioactive forms, potentially facilitating its transport in tissue and.
with O2  and superoxide (Kanner J, 1991).
18
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importantly in the lungs, mitigating the toxicity arising from the reaction of NO
i
4. Reactions with superoxide (Og.-)
NO reacts rapidly with superoxide in both gaseous phase and aqueous solution to
-
form peroxynitrite anion (ONOO). The subsequent protonation and 
decomposition of ONOO to species with NO^' and OH is an important 
mechanism by which NO may exert toxic and cidal effects under physiological 
conditions. Peroxynitrite anion and peroxynitrous acid are strong oxidising agents 
and their decomposition products, OH and NO^' facilitate lipid peroxidation (Radi 
R, 1991a. Radi R, 1991b)
IEach of the products of these reactions with oxygen, superoxide and transition 
metals - NOx species, peroxynitrite and metal-NO adducts support additional 
nitroactive reactions. S-nitrosothiol formation predominates due to the greater 
prevalence and reactivity of thiols in biological systems (Stamler JS, 1992a).
Accordingly, metal and thiol containing proteins seiwe as major target sites for 
NO. The essential components of NO responsive signaling circuitry - signaling 
proteins, ion channels, receptors, enzymes and transcription factors all contain 
either transition metals or thiols strategically located at either allosteric or active 
sites allowing regulation o f the protein by nitrosylation of or redox reaction with 
the metal or thiol component. i
19
1.3 SYNTHESIS OF NITRIC OXIDE IN THE LUNGS
NO is foimed in vivo by nitric oxide synthase (NOS), which catalyses the 5 
electron oxidation o f the guanido nitrogen moiety of L arginine to citrulline via 
N-hydroxyl-L-arginine (figure 1).
The NOS reaction involves an initial hydroxylation of L arginine to generate N-y- 
hydroxy-l-arginine (NHA) (Stuehr D, 1991.). This step is thought to involve the 
haem moiety o f NOS, which directly oxidises NHA. There are at least three 
isoforms of NOS (described in detail later) designated NOS I-III. The enzyme 
utilises O2  and NADPH as cosubstrates and thiol, tetrahydrobiopterin, flavin 
adenine dinucleotide (FAD) and flavin mononucleotide (FMN) as co factors 
(Fostermann U, 1991. Mayer B, 1990.). In the lungs, macrophages, neutrophils, 
eosinophils, mast cells, iNANC neurons, fibroblasts, vascular smooth muscle 
cells, pulmonary arterial and venous endothelial cells and pulmonary epithelial 
cells have all been shown to be capable of expressing NOS and generating NO. 
(Hibbs JB, 1987. Jorens PG, 1991. Rimele TJ, 1988. Bissonnette EY, 1991. Bult
H, 1990. Belvisi MG, 1991. Jorens PG, 1992). The most distinctive phenomenon 
about NO production by these thiee isoforms is that NO produced by NOS II (see 'I
later) is about 1 0 0 0  fold greater than that produced by the other two isoforms 
(Vodovotz Y, 1994). This has direct bearing on the function o f NO and is 
discussed in chapter 1.6.3.
20
H2N NH2+r
NH
+H3N COO - 
L- arginine 
NADPH — C \  O2
H4 Biopterin
H2N N-OHr
NH
H2 Biopterin
+H3N COO - 
N® -OH-L-arginine
NADPH
NH
NO
Thiol
S-nitrosothiol
+H3N COO - 
L-citrulline
FIGURE 1. Formation of NO by NOS. A guanido nitrogen of L-arginine is oxidised in the 
presence of cosubstrates NADPH and molecular oxygen to yield NO. Calmodulin, 
flavoproteins, tetrahydrobiopterin and thiol are enzyme cofactors. NO is converted to more 
stable RS-NO under physiological conditions, possibly to prevent ‘suicidal’ inhibition of 
the NOS haem moiety.
1
It is widely assumed that NO diffuses passively from the cytosol of its cell of 
origin to neighbouring target cells to elicit a response (Roberts J, 1992). Its short 
half life of between 0.1 and 5 seconds in physiological systems (Palmer RMJ, 
1987. Kelm M, 1990) has led to the hypothesis that NO is a locally acting 
substance, perhaps behaving in a paracrine fashion. It is likely that its short half 
life and reactivity limits it to its site of action but subsequent activity is 
deteimined by the amount o f NO produced and presence of other molecules in the 
micro environment.
f"A
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Three NOS genes have been identified to date (table 2). These are called types I- 
III, according to the order of their discovery. Type I (neuronal NOS) is a 29 exon
22
1.4 MOLECULAR BIOLOGY OF NITRIC OXIDE SYNTHASES
Two constitutive and one inducible nitric oxide synthases have been described. 
One o f the constitutive enzyme (eNOS) was restricted to endothelium and the 
other (nNOS) was found in central and peripheral neurons, neuroblastomas, 
human skeletal muscle, (3 cells of pancreatic islets and epithelial cells o f bronchioli, 
uterus, and stomach. These constitutive NOS’s lie dormant until and so long as a 
rise in intracellular calcium sustains the binding of calmodulin, leading to NO 
release over several minutes (Malinski T, 1992). An inducible NOS was found to 
be expressed in many cell types after challenge with immunological or 
inflammatory stimuli (Nathan C, 1992) and thereupon generates large amounts of 
NO. Tonic activation of this isoform is thought to reflect its ability to bind 
calmodulin even at the trace levels of calcium found in resting cells (Cho HJ,
1992).
gene found on human chromosome 12q24.2 and extends over 100 kb (Kishimoto 
J, 1992. Hall AV, 1996). Type II NOS (iNOS) is found on 17cen-qll,2, has 26 
exons and is 37 kb in size (Chartrain N, 1997. Marsden PA, Heng HHQ 1994). 
and type III or the endothelial (eNOS) gene, resides at 7q35-7q36 and comprises 
26 exons that span 21 kb (Marsden PA, Heng HHQ, 1993. Robinson LJ, 1994).
11
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1.4.1 REGULATION OF NOS I EXPRESSION
NOS I was the first NOS cDNA ever cloned and this was done from rat 
cerebellum by Bredt and Snyder in 1990 (Bredt DS, 1990). Since then it has also 
been cloned in mouse (Ogura T, 1993) and humans (Nakane M, 1993) and 
appears to be highly conserved across species. The human NOS I cDNA has an 
open reading flame of 4299 nucleotides encoding for a protein with a molecular 
weight o f 161 kDa. The NOS I gene is approximately 160 kb in size and is
23
Traditionally, types I and III NOS’s are thought to be constitutively expressed and 
inteimittently produce small pulses of NO that mediate physiological activities. In 
contrast, type II or inducible NOS is expressed in response to external stimuli and 
produces large, sustained amounts of NO. Recent reports, have challenged this 
paradigm of constitutive and inducible NOS expression. Full type I and III NOS’s 
activity appear to depend upon cytokine induction of GTP cyclohydrolase I, the 
rate limiting enzyme in the synthesis of tetrahydrobiopterin (Werner-Felmayer G,
1993). Conversely NOS II is also constitutively expressed in some tissues and cell 
types, such as the large airways of humans and certain mononuclear cell lines 
(Kobzik L, Bredt DS, 1993. Mannick JB, 1994. Hoffman RA, 1997. Guo FH,
1995). These observations highlight the complexities of NOS gene expression and 
the fact that NOS expression whether induced or constitutive is not just limited to 
features of the gene for a specific isoform but also to the cell type and stimulus 
involved in NOS expression.
composed of 29 exons and 28 introns (Hall AV, 1996). The major transcription 
start site is 28 nucleotides downstream from a TATA box. Translation starts in 
exon 2 and terminates in exon 29. Sequence of the 5’ flanking region shows 
several potential cis acting DNA element including NF-1, AP-2, CREB/ATF and 
NF-kB like motifs (Hall AV, 1996). Transcriptional control o f the human NOS I 
gene involves two distinct 5’ untranslated regions that are encoded through the 
use of two closely linked but separate promoters for human nNOS gene 
transcription (Xie J, 1995). This results in alternative splicing o f exon 1 in the 5’ 
untranslated region of the niRNA but does not affect actual size of the translated 
NOS I protein.
Conditions such as cerebral ischaemia (Zhang ZG, 1994) and chronic salt loading 
(Kadowaki K, 1994) have been shown to upregulate NOS I mRNA in rat brain 
although the precise molecular mechanisms responsible have not been elucidated. 
The 3’ imtranslated region in the 29th exon of the human NOS 1 gene contains a 
dinucleotide microsatellite repeat and multiple alleles of the repeat exist in normal 
individuals indicating polymorphism (Hall AV,1996).
Post-transcriptional control of the NOS I gene also exists in the foiin of 
alternative mRNA splicing. This structural diversity was first reported in mouse 
brain where about 5% of neuronal NOS I transcripts lacked two exons encoding 
105 amino acids from position 504 to 608 (Ogura T, 1993). Similar structural 
diversity was also identified in the human cerebellum. This recombinant variant
24
was unable to convert L-arginine to NO and L citrulline but did retain NADPH 
diaphorase activity.
With the cloning of NOS I came the recognition that NOS I gene is also highly 
expressed in skeletal muscle and suggested a possible novel function of NO in 
the skeletal muscle. An additional alternatively spliced isoform of NOS I is 
further identified which is expressed in differentiated skeletal muscle (Silvagano 
F, 1996). Designated neuronal NOS-p (nNOSp), this NOS I isoform is slightly 
larger than NOS I expressed in brain due to an inserted 192 bp alternatively 
spliced segment between exons 16 and 17. This isoform has similar catalytic 
activity to cerebellar NOS I and this protein was found only in skeletal muscle, 
penile corpora cavernosa, urethia , prostate and heart but not spleen, liver, kidney 
or brain by antibody staining in rat tissues. This demonstrated that alternative 
mRNA splicing can function as a mechanism for tissue specific regulation of 
NOS I.
1.4.2 REGULATION OF NOS II EXPRESSION
Human NOS II was first cloned in 1993 from LPS and cytokine stimulated 
primaiy human hepatocytes (Geller DA, 1993a). The sequence of hepatocyte 
NOS II clone reveals a 4145 bp DNA containing 3459 bp open reading fi-ame, 
MW - 131 kDa. The human NOS II gene itself is about 37 kb long and composed 
of 26 exons and 25 introns. This genomic stmcture is similar to that of the human
25
NOS I and II genes, suggesting divergence from a common ‘ancestral’ NOS gene. 
Compared to the murine macrophage NOS II, the human hepatocyte NOS II 
sequence is 6  amino acids longer in the amino portion of the protein and 3 amino 
acids longer at the carboxyl terminus. Similar to other NOS isoforms, NOS II 
contains consensus recognition sites for the cofactors FMN, FAD and NADPH in 
the carboxyl half of the protein which have been shown to be important for NOS 
II enzyme activity. In addition, a consensus calmodulin recognition site is also 
present. Overall the human hepatocyte NOS II displays 80% sequence identity to 
its murine macrophage counterpart at both the nucleotide and amino acid levels. It 
has 51% and 53% amino acid sequence homology with the NOS III and NOS I 
proteins respectively (Geller DA, 1998).
A number of agents are known to induce NOS II expression. Most o f these appear 
to act in synergy with an interferon (IFN) or IFN inducing agent like bacterial 
lipopolysacchaiide (Nathan C, 1992). The major inducers are the 
proinflammatory cytokines (ILlp, TNFct and IFNy), but the list includes 5,6- 
dimethylxanthenone-4-acetic acid (Thomsen L.L, 1992), picolinic acid (Melilo G, 
1993), cAMP elevating agents (Hortelano S, 1993. Koide M, 1993. Imai T, 1994), 
UV light (Warren JB, 1994) and ozone (Pendino KJ, 1993). However, to put the 
list in perspective, the most important observation about NOS II expression is that 
LPS and IFNy are the strongest inducers of NOS II in monocytes (de Vera ME,
1996). In contrast, most tissue derived cells, including hepatocytes, mesangial 
cells, vascular smooth muscle cells have NOS II which are more sensitive to ILIp
I
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and TNFa. In nearly all cell types, LPS, IFNy, ILip and TNFa enhance NOS II 
expression synergistically.
It is worth noting that rodent cells are more easily triggered to express NOS II 
than human cells, therefore some animal data are unlikely to be applicable to 
human (Beck KF, 1999).
In terms of speed o f expression, studies on human NOS II in a human epithelial 
cell line (AKN-1) and primary human hepatocytes showed that when stimulated 
with the cytokine mixture of TNFa, IL ip  and IFNy, NOS II mRNA was observed 
at 2 hours, peaked at 4 hours and diminished by 24 hours (de Vera ME, 1996). A 
time dependent rise in NO release was seen that lagged behind the NOS II mRNA 
expression. Onset of NO production occun'ed 6 - 8  hours after induction of NOS II 
but once induced, this expression persisted for days.
The human NOS II promoter was characterized by de Vera et al in 1996 (de Vera 
ME 1996). It differs significantly from its murine and rodent counterpart. 
Cytokine responsive elements are found upstream from -3.8 kb in the promoter 
(de Vera ME, 1996) in contrast to the murine NOS II promoter where only 1 kb of 
the proximal 5’ flanking region is required to confer LPS and cytokine 
inducibility (Xie QW, 1993). Analysis of the first 400 bp upstream of the human 
transcriptional initiation site revealed the presence of thi'ee interferon gamma 
response element (y-IRE) (Pearse RN, 1991), reported to be involved in IFNy
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induced gene expression, an NF-kB site, conserved with the murine promoter, 
reported to be involved in cytokine and LPS stimulated gene expression and a 
degenerative TNF-RE site which confers responsiveness to TNFa. NF-kB is the 
main transcription factor involved in the regulation of NOS II expression. The 
activation and translocation of this transcription factor to the nucleus leads to a 
coordinated increase in the expression of many genes including IL lp , TNFa, IL6 , 
IL 8  and GM-CSF, and adhesion molecules responsible for recmitment of 
inflammatory cells. In turn, many stimuli activate NF-kB, including cytokines, 
protein kinase C activators, viruses and oxidants. Thus induction of NOS II by 
this pivotal transcription factor involves NO in a coordinated increase in the
expression of many genes whose products mediate inflammatory and immune 
responses (Xie QW, 1994).
There is evidence to suggest that NOS II is expressed in response to factors other
than immunological and inflammatory signals. NOS II have been detected 
constitutively in kidneys o f noimal rats (Tojo A, 1994) and importantly, in normal 
airway epithelia (Kobzik L, 1993, Watkins DN, 1997). In the last, it has been 
argued that this may be a residuum of repeated exposures to airborne stimuli 
rather than true constitutive expression. If NOS II is constitutively expressed, it 
suggests that it may serve a physiological role in addition to its pathological ones.
Although NOS II is thought not to be calcium sensitive, the calcium chelating 
agent ethylene glycol bis (p aminoethyl e th e r ) -N A ,'- te tra -a c e ta te  (EGTA)
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and the calmodulin antagonist, trifluoroperazine decreased NOS activity by 50- 
60% (Sheiman PA, 1993). It is likely that some low level o f calcium is required 
for optimal calmodulin binding to human NOS II.
More recent findings suggest that there are three main signaling pathways 
responsible for NOS II expression. Induction in murine macrophages is mediated 
by IFN y activated sites and IFN y responsive elements in the promoter (Xie QW,
1993. Martin E, 1994). In rat mesangial cells, binding of NF-lcB at the appropriate 
site on the NOS II promoter is essential for the induction of NOS II by IL ip  
(Eberhardt W, 1998). In contrast, endothelin 1 inhibits cytokine induced NOS II 
expression without affecting NF-kB binding suggesting additional mechanisms 
that are essential for cytokine induced NOS II expression (Beck KF, 1996). For 
the induction of NOS II by cAMP, entranced binding of the transcription factors, 
CAAT enhancer-binding protein (C/EBP) and cAMP responsive element binding 
protein (CREB) on the NOS II promoter has been reported (Eberhardt W, 1998).
One o f the controversies suiTounding NOS induction in inflammatory situation is 
the difficulty encountered in finding NOS II expression in human macrophages 
(Denis M, 1994). While the debate continues, it is clear that human macrophages 
have the ability to produce NO under certain inflammatory conditions but at least 
one group has confirmed a transcriptional basis for hyporesponsiveness o f the 
NOS II gene promoter in human macrophages to LPS and IFNy compared to 
murine macrophages (Zhang X, 1996). Two explanations for this
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TGFp also partially prevents induced NO synthesis. Suppression of NOS II 
expression by TGFp has been shown in macrophages (Ding A, 1990) mesangial 
cells (Pfeilschiffer J, 1991) and cardiac myocytes (Roberts AB, 1992). However,
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hyporesponsiveness were found - i. multiple inactivating nucleotide substitutions
in the human counterpart of the enliancer element that has been shown to regulate
LPS and IFNy induced expression of the murine NOS II gene and ii. an absence
of one or more nuclear factors in the human macrophages that are required for 
.maximal expression of NOS II. This may also illustrate the differences between 
molecular regulation of the rodent and murine NOS II and human NOS II.
Equally important in knowing what upregulates NOS II expression is knowing
what turns it off. Glucocorticoids are known to inhibit induced NO synthesis in
several cell types (Nathan C,1992. DiRosa M, 1990. Knowles RG, 1990.
Radomski MW, 1990). In rat hepatocytes, the effect is a result o f decreased NOS
II transcription due to the ability of dexamethasone to upregulate I-kB expression 
.and inhibit cytokine stimulated NF-kB activity (Geller DA, 1993b) The latter is 
thought to be mediated by direct binding of glucocorticoid receptor to NF-kB, 
preventing it from binding to kB sites on NOS II. Kleiniert found that 
dexamethasone inliibited cytokine induced NOS II mRNA in human A549 
epithelial cells by 70% and that this inhibition was mediated in part by down 
regulating activation of NF-kB, without an increase in I-kB mRNA levels 
(Kleinert H, 1996).
this effect is not uniform with different cells and species (Kunz D, 1996). This 
underscores the complexity o f NOS II regulation, lending support to the notion 
that species, tissue and cell-specific mechanisms are likely to be important in 
controlling NOS II expression. Induction of heat shock response by hyperthennia 
blocked subsequent NOS II expression in AKN-1 human liver cells and a similar 
suppression has been reported in brain astroglial cells (Feinstein DL, 1996). The 
induction of the heat shock response may be an adaptive defense mechanism that 
prevents over expression o f NOS II during inflammatoiy conditions.
In teims of post transcriptional control, TGFp has been found to suppress 
macrophages NOS II expression by decreasing NOS II mRNA stability and 
translational efficiency (Vodovotz Y, 1993). There are also reports that 
dexamethasone can increase NOS II mRNA stability in IL lp  stimulated rat 
mesangial cell and vascular smooth muscle cells (Kunz D, 1996. Perrella MA, 
1994.). There are also reports o f differential NOS II protein detection in different 
tissue - thus, although NOS II mRNA can be readily detected in cardiac myocytes 
and hepatocytes, NOS II protein and NO synthesis are not found in the former 
(Luss HL, 1997). These data suggest that cell-specific post transcriptional 
mechanisms may operate; but it is unclear if this is secondary to rapid 
degeneration o f NOS II mRNA or a block in translational machinery.
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1.4.3 REGULATION OF NOS III EXPRESSION
The endothelial NOS cDNA was cloned from cultured bovine (Lamas S, 1992)
and human endothelial cells (Marsden PA, 1992). The cDNA has an open reading
frame of 3609 nucleotides encoding a protein with a molecular weight of 133
kDa. The human NOS III protein has approximately 50% homology with NOS I
isoform (Geller DA, 1998). The gene is 21 kb in size and composed of 26 exons
and 25 introns (Nadaud S, 1994). A highly polymorphic dinucleotide repeat (CA)„
occurs within intron 13. The human NOS III promoter is ‘TATA-less’ but does
contain a CCAAT box at -286. The 5’ flanking region also contains proximal
promoter elements Spl and GATA which are consistent with constitutively-
expressed endothelial cell genes. The 5’ flanking region also contains putative
sequence motifs for AP-1 and AP-2, NF-1, heavy metal and shear-stress 
,responsive elements (Marsden PA, 1993). Haemodynamic shear stress in vitro 
.(Nishida K, 1992) and chronic exercise in vivo (Sessa WC, Circ Res 1994) have 
been shown to increase the expression of NOS III mRNA, suggesting possible 
transcriptional regulation mediated via the shear stress response element in the 
promoter.
Hypoxia appears to exert different effects on NOS III expression. In rat and 
porcine arterial endothelial cells, chronic hypoxia up-regulated NOS III 
expression (Le Cras TD, 1996. Xu X-P, 1995). However, exposure of human or 
bovine endothelial cells to low oxygen tension resulted in a decrease in the
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transcript for endothelial NOS and a corresponding fall in NOS protein (Phelan 
MW, 1996). Furthermore, the ability of endothelial cells exposed to chronic 
hypoxia to produce NO in response to bradykinin, a stimulator of NOS III 
activity, was also impaired. The addition of actinomycin-D abrogated the hypoxic 
effect o f NOS III transcripts, suggesting that new gene transcription is required 
for NOS III suppression.
In addition to transcriptional control, post transcription regulation has also been 
identified for the human NOS III gene. TNFa was found to decrease bovine aoidic 
endothelial cell and human umbilical vein endothelial cells (HUVECS) mRNA.
In nuclear mn on assays TNFa did not change the rate of NOS III gene 
transcription assays in HUVECs but it did shorten the half life of NOS III mRNA 
(Yoshizumi M, 1993). Under basal conditions the NOS III mRNA was very stable
.
in HUVECs with half life o f 48 hours; exposure to TNFa decreased this to 3 
hours. Thus, TNFa decreases NOS III mRNA levels by increasing the 
degradation. The mRNA destabilization was prevented by cycloheximide, 
implying that TNFa may induce a protein responsible for message degradation.
1.4.4 POST TRANSLATIONAL CONTROL OF NITRIC OXIDE 
SYNTHASE PROTEINS
The NOS protein is a complex enzyme involving several tightly bound redox 
cofactors that are apparently organised into discrete domains that can be
33
■‘I;
,1I
S
associated with a particular activity (Fostermann U, 1991). The enzyme has
significant homology to NADPH cytoclrrome P450 reductase and has been shown
to cany out P450 chemistiy in the formation of NO (Bredt DS, 1991). Given that 
the noi*mal function o f P450 reductase is to supply reducing equivalents to 
cytochrome P450, it has been assumed that this domain in NOS serves the same 
function.
All three NOS isoforms share features of post translational modification.
Mechanisms of post translation control include NOS protein stability, 
dimerization, phosphorylation, subcellular localisation, co-factor binding and 
availability of substrates L- arginine and molecular oxygen (Fostennann U, 1995).
Besides suppressing NOS II expression (see chapter 1.4.2), TGFp also accelerates 
the degradation of NOS II protein in mouse macrophages (Ding A, 1990.
Pfeilschiffer J, 1991). However, it is unknown if similar effect is exerted on other 
NOS isoforms.
1
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.Tetrahydrobiopterin appears to be a rate limiting co-factor in mouse fibroblasts,
rat vascular smooth muscle and human endothelial cells (Gross SS, 1993). Full 
NOS II and NOS III activity appear to be dependent on the induction of GTP 
cyclohydrolase I, the rate limiting enzyme in biopterin synthesis. The same kinds 
of immune and inflammatory agents that induce NOS II in endothelimn are able 
to capacitate endothelial NOS III within intact cells by satisfying its
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tetrahydrobiopterin requirements (Suschek C, 199). In this way, the activity of a 
constitutive enzyme may appear partially inducible. However, this has only been 
shown in vitro, where the naturally occurring tetrahydrobiopterin levels fall 
rapidly when cells are cultured, raising the possibility that the obseiwation may be 
a cell culture induced artifact.
One o f the most important deteiminant o f protein stability could well be the 
product of the protein itself, nitric oxide. NO can inhibit NOS (Rogers NE, 1992. 
Griscavage JM, 1993) and is known in vitro to have a negative feedback ability 
(Assreuy J, 1993). However, it is not clear whether the relevant reaction of NO is 
with the thiol-bound haem of NOS, with a critical thiol or other amino acid side 
chain on the enzyme, or indeed with a redox-sensitive co-factor.
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1.5 THE BIOLOGICAL EFFECTS OF NITRIC OXIDE
NO can be viewed as an ubiquitous molecule with three broad remits in its 
physiological role - as a signaling molecule, a neurotransmitter and a molecule 
possessing its own specific activities.
1.5.1 NITRIC OXIDE AS A SIGNALING MOLECULE
One o f the most basic activities of NO is its role as a signaling molecule in cell 
responses. This is possibly one the most intense areas of basic NO research in 
recent years. The most physiologically relevant action of NO in this capacity is the 
activation of soluble guanylate cyclase by nitrosation of its haem moiety (Ignarro 
LJ, 1990). The subsequent increase in cGMP level alters the activity of tlnee main 
target proteins: i. cGMP regulated ion channels, ii. cGMP regulated 
phosphodiesterases and iii. cGMP dependent protein kinases (Schmidt HHHW, 
1993).
NO appears to activate all thi'ee parallel mitogen activated protein kinase 
(MAPK) cascades in Jurkat T cells (Lander HM, 1996) and increase the activity of 
protein kinase C. However, these effects do not appear consistent and in different 
cell types may have the opposite effect (Caselli A, 1994. Callsen D, 1998). The 
current conclusion from a large number of studies is that NO can, in principle 
deliver signals to all major MAPK cascades including the classical ERK, 
SAPK/NK and p38 kinase cascades as well as the JAK/signal transducer and
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activator of transcription (STAT) pathway (Beck KF, 1999). An integration of 
these signals lead to cell type specific responses that critically depend on 
interactions between individual constituents of a cell and the components of the 
different signaling cascades. These cascades o f events then trigger the 
phosphoiylation of key nuclear proteins, including transcription factors and finally 
may lead to alteration in gene expression.
Increasing evidence is also accumulating that NO preferentially alters 
transcription factors that are sensitive to changes in cellular redox status (e.g. NF 
kB and AP 1) (Sen CK, 1996). Reported mechanisms include scavenging of 
reactive oxygen intemediates in the cell (and therefore inhibiting the activation of 
NF-kB) (Zeiher AM, 1994. Peng HB, 1995), direct inhibition of the DNA binding 
activity o f NF-kB family proteins and direct modification of transcriptional 
activators e.g. AP 1 (Tabuchi A, 1994).
An increasing number of genes have been shown to be under the regulatory 
control o f NO - extracellular matrix proteins (Chatziantoniou C, 1998) and their 
corresponding proteases (Sasaki K, 1998), growth factors (Tsurumi Y, 1997. Chin 
K, 1997), hormones (oestrogens) (Wang H, 1998), cytokines (TNFa stimulated 
IL 8  is inhibited by NOS inhibitor in dose dependent manner) (Van Dervort AI, 
1994. Villarete LH, 1995. Nuhl H, 1997) and enzymes (Hartsfield CL, 1997).
NO has also been established as a potent inducer of apoptosis in certain cell types 
(Brune B, 1998. Mebmer UK, 1994) but contradictory effects have been reported
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in others, with NO displaying anti-apoptotic effects in lymphocytes, eosinophils, 
hepatocytes and endothelial cells (Nitsch DD, 1997. Dimmeler S, 1997).
Therefore, most physiological responses are triggered by moderate concentration 
o f NO through the activation of soluble guanylate cyclase. High concentrations of 
NO operate in part through redox sensitive regulation of transcription factors and 
gene expression and alter, on a longer term basis, the capacity of the cells to deal 
with stress conditions.
1.5.2 EFFECTS OF NITRIC OXIDE IN HOST DEFENCE AND IMMUNO- 
REGULATION
NO formation may have originated as an ancient first line of defence for metazoan 
cells against intracellular parasites like L. major, T. gondii and M. Leprae. 
Infection in humans and animals are often associated with significant increase in 
systemic NO production in plasma and urine (Anstey NM, 1996. Evans TG, 1993. 
Ochoa JB, 1991.). Microbial products like LPS and lipoteichoic acid stimulate the 
expression of NOS II in epithelial and macrophages. Production o f NO in many 
animal models can be directly correlated with the ability of the host to contain 
microbial proliferation. Abrogation of NOS II activity produces dramatic 
increases in microbial burden (Stenger S, 1996. MacMicking JD, 1997). In vitro 
studies o f phagocytic cells and a variety of microbial targets have demonstrated 
cytokine inducible microbiostatic or microbicidal activity which is L arginine 
dependent and inhibitable by NOS inhibitors. Indeed, there is good evidence that
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NO release induced in septic shock is a major contributor to cardiovascular 
collapse. Finally, experiments using the NOS II knockout mouse showed that 
these animals were less capable of controlling replications of Listeria 
monocytogenes mid Leishmani major (MacMicking JD, 1995).
Although it is has been shown in vitro that NO has a growth preventing and lethal 
cidal effect, there is still little information on the biochemical mechanism by 
which NO blocks the growth of or kills microorganisms. One paper did show that 
foimation o f nitrotyrosine around bacteria aids in the ingestion by phagocytes 
(Evans TJ, 1996). There is also accumulating data to suggest that NO encourages 
the production of IFNy which is cmcial in the contaimnent o f intracellular 
pathogens like the mycobacteria spp. since this cytokine activates macrophages 
and other effector cells (MacMicking JD, 1997),
I
The role of NOS II produced -NO in the immune system comprises both effector 
and regulatory functions. There is considerable evidence that NOS II produced 
NO can modulate cytokine production from macrophages, T cells, endothelial 
cells and fibroblasts and lymphocyte proliferation. Low levels of NO have been 
implicated in lymphocyte activation and proliferation. NO donors like sodium 
nitropmsside increase lymphocyte uptake of glucose (an early event in 
lymphocyte activation) and stimulate TNFa production and NF-kB binding 
activity (Billiar TR, 1995. Farrell AJ, 1996). NO also enhances activity of tyrosine 
kinase p56 which is implicated in lymphocyte signaling events. NOS inhibitors 
and L arginine depletion impairs phytohaemagglutinin (PHA) stimulated
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proliferation (Efron DT, 1991). Both in vitro and in vivo, L arginine has also been 
shown to enhance natural killer and lymphokine activated killer activity. In 
contrast, high concentrations of NO suppress antigen presenting cell activity and T 
cell proliferation (Mills CD, 1991. Meiryman PF, 1993). There is evidence that 
NO exerts different effects on discrete subpopulations of T cells, for example by 
inhibiting secretion o f IL2 by murine Thl cells and increasing secretion of IL4 by 
Th2 cells (Chang RH, 1997). These observations however, differ from those o f 
Bauer who reported that production of Thl and Th2 associated cytokines are 
equally impaired by NO donors (Bauer H, 1997).
NO has been shown to promote apoptosis in macrophages, CD4+/CD8+ 
thymocytes, chondrocytes and pancreatic (3 islet cells (Blanco FJ, 1995. Kitajima 
I, 1994. Ankacrona M, 1994. Fehsel K, 1995. Albina IE, 1997). The mechanisms 
appears to require the activation of poly(ADP-ribose) polymerase and foimation 
of nitrotyrosine and is opposed by Bcl-2 (Melkova Z, 1997). However, in low 
concentrations (<1 pM), NO has been reported to inhibit apoptosis o f hepatocytes, 
B lymphocytes and eosinophils (Kim YM, 1997).
1.5.3 NITRIC OXIDE IN INFLAM MATION
Endogenous NO is widely hailed as a double edged sword. In high concentrations 
and under abnormal conditions and environment it has deleterious effect, while in 
small pulses it mediates physiological processes.
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NOS II is induced in response to excessive cytokine production. This is a non­
specific event which occurs in a wide variety o f cells. Increased production or 
expression o f NOS II has been implicated in sepsis (Hutcheson AR, 1990. Petros 
A, 1991), ulcerative colitis (Middleton SJ, 1993), psoriasis (Kolb-Bachofen V,
1996), rheumatoid arthritis (McCartney-Francis N, 1993. St Clair EW, 1996), 
multiple sclerosis (Parkinson IF, 1997), type 1 diabetes (Kolb H, 1992), asthma 
(Kharitonov SA, 1994. Alving K, 1993) and connective tissue diseases (Belmont 
HM, 1997). In all o f these diseases the pro-inflammatory cytokines, TNFa, IL lp  
and IFNy have been implicated. Therefore, the finding of increased NO production 
is often viewed as a reflection o f an immune activated state where inflammatoiy 
cytokines and other mediators have upregulated NOS II in diverse tissues.
Several classic signs o f inflammation are reversed by NOS inhibitors. Mulligan et 
al, using a rat model of immune complex lung injury, showed that inhibitors of 
NO synthesis were protective whereas L arginine exacerbated tissue injuiy 
(Mulligan MS, 1991). IL2 infusion in healthy mice results in the expression of 
NOS II in numerous tissues including the endothelium and muscles of the thoracic 
wall with accompanying pleural effusion and pulmonaiy oedema (Omvic A,
1997). Treatment of these mice with NOS inhibitors reduced IL2 induced 
pulmonary oedema and pleural effusion.
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In keeping with its dual roles, NO also possesses anti inflammatory effects (Kubes 
PM, 1991). It is able to inhibit leukocyte adhesion and oxidant production and in 
direct contrast to Mulligans’ work on IL2 infusion in mice, Bouchier-Hayes
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reported that NO attenuates IL2 induced lung injury (Bouchier-Hayes D, 1997). 
These seemingly conflicting data underscore the complexity o f defining the role of 
NO in inflammation. Wliile excessive NO production is generally associated with 
tissue injury, NO constitutively produced by endothelium is believed to play a 
protective role in the microvasculature (Stamler JS, 1992. Kubes PM, 1991). Here, 
NO inhibits platelet and neutrophil adhesion to endothelial monolayers as well as 
inhibiting leukocyte superoxide anion production (Clancy RM, 1992. Utieirez 
HH, 1996). NO has also been shown to inhibit mast cell degranulation and to 
block upregulation o f p selectin expression (Massini E, 1996). These vascular 
defensive properties o f NO in tissues have been demonstrated by its capacity to 
protect against tissue injury in vivo in myocardial ischaemia reperfusion injury 
and in ARDS (Roissant R, 1993. Guidot DM, 1995).
A complex relationship is also emerging between NO and the cyclo-oxygenase 
(COX) pathways, the latter involved in the production o f prostaglandins. Like 
NOS, COX has constitutive and inducible pathways and COX 2 is the inducible 
form o f the enzyme. A variety o f cells e.g. endothelial cells and macrophages 
produce NO and prostaglandins simultaneously in response to cytokines and other 
activators. The paracrine effects of these molecules are often similar, including the 
capacity to relax smooth muscle, inhibit platelet and neutrophil adhesion and 
neutrophil oxidant production. Small amounts of NO appear to stimulate COX 
activity, possibly by scavenging superoxide which usually inhibits COX activity 
(Salvemini D, 1996. Amin AR, 1997. Salvemini D 1993).
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Wink and coworkers explain these conflicting roles of NO by its physiological 
chemistry (Grisham M, 1999). Indeed, it does appear that the chemistry of NO 
within its micro environment as described in chapter 1 . 2  is likely to dictate the type 
of effect NO has on biological systems. This together with the amount of NO 
produced are likely to be the most important determinants of the role of NO in any 
circumstance. Thus NO produced in small fluxes and interacting directly with a 
biological molecule or target usually results in protective effects. For example, 
reaction of NO with the haem moiety in guanylate cyclase and subsequent 
synthesis o f cGMP results in anti inflammatoiy effects such as regulation of 
vascular tone, inhibition of platelet aggregation and leukocyte-endothelial 
interactions (Wink DA, 1997). In the NO-COX interactions, small amounts of 
NO stimulate production of anti inflammatory prostaglandins as described above 
(Savemini DT, 1993 and 1996, Amin AR, 1997) but sustained over-production of 
NO actually inhibits COX activity.
Large amounts of NO production appear to be the principal cause of 
inflammation. The effects of NO become ‘indirect’ with the formation o f reactive 
nitrogen species, mainly from the interaction of NO and superoxides and oxygen. 
Peroxynitrite itself is a powerful oxidant, oxidizing thiols, nitrating tyrosine 
residues, nitrating and oxidising guanosine, degrading carbohydrates, initiating 
lipid peroxidation and cleaving DNA (Wink DA, 1998).
Another way of promoting inflammation is by removal o f NO adducts with anti
inflammatory functions. S-nitrosothiol adducts are readily formed during auto-
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oxidation o f NO (Stamler JS, 1992). In the context of inflammation, s-nitrosothiol 
can inhibit leukocyte adhesion to microvascular endothelial cells by nitrosation of 
sulphydryl groups on surface of endothelium and polymoiphonuclear neutrophils 
which are critical for adhesion and infiltration (Kubes PM, 1991). The presence of 
superoxide in chronic inflammatory situations has been shown to deplete the 
amount of s-nitrosothiol and therefore promote adhesion and infiltration of 
inflammatory cells (Marietta MA, 1994).
1.6 THE BIOLOGICAL ROLE OF NITRIC OXIDE IN THE AIRWAYS
In the airways, NO serves tln*ee major physiological roles - as a vasodilator,
bronchodilator and in mediating host defence. The first two roles are discussed 
below, its function in host defence has been discussed in chapter 1.5.2. NO is also 
implicated in the pathophysiology of a number o f airways diseases.
1.6.1 ROLE IN PULM ONARY VASCULAR TONE
In the airways, NO mediates the vasodilator action of acetylcholine in animal and
human pulmonary vessels and acts as a braking mechanism against pulmonary 
.vasoconstriction (Furchgott RF, 1980. Dupuy PM, 1992. Li CG, 1991). Release of 
NO firom endothelial cells in pulmonary circulation counteracts hypoxic
vasoconstriction (Liu SF, 1991. Persson MG, 1990) and L-NMMA (a non specific 
.NO inhibitor) injected into pulmonary artery causes an increase in pulmonary
vascular resistance (Blitzer M, 1994). Pulmonary arterial and venous endothelial 
cells release NO in response to a variety of agonists such as acetylcholine and 
bradykinin that relax pulmonary arterial, venous and lymphatic smooth muscle 
(Ignano LJ, 1987. Cherry PD, 1990. Liu SF, 1992). NO mediates both 
endothelium dependent and endothelium independent iNANC relaxation of guinea 
pig pulmonary arteiy in vivo (Liu SF, 1992). It also modulates pulmonary arterial 
contractile responses to catecholamines (Liu SF, 1992) and PGF2a (Namiki A, 
1992), reverses hypoxic pulmonary vasoconstriction (Frostell CG, 1991) and 
mediates flow-enhanced decreases in vascular resistance (Cook JP, 1990). Its
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importance in human physiology is shown by the finding of decreased expression 
of NOS in pulmonary vascular endothelium of patients with both primaiy and 
secondaiy forms o f pulmonary hypertension (Giaid A, 1995). This suggests that 
sustained attenuation of pulmonaiy vascular NO production is associated with 
clinically significant alterations on pulmonary vascular tone.
Under physiological conditions, the pulmonary vasculature exhibits a low degree 
o f resting tone, and operates at pressures approximately 2 0 % of those in the 
systemic circulation. It has been suggested that this is largely secondaiy to 
continuous NO release, because of its vasodilatoiy effects as described above. 
This hypothesis is not universally accepted. NOS inhibitors enhance pulmonaiy 
vascular tone in some models but have no effect in those that attempt to keep 
cardiac output constant (Leeman M, 1996). Also, clu*onic inliibition of NOS in 
rats causes systemic but not pulmonaiy hypertension (Hampl V, 1993).
Because NO appears to relax both vascular and airways smooth muscle, it has 
been proposed to serve as a mediator of regional airflow/ blood flow matching. 
The use o f inhaled NO, however has shed some light on the possible role in these 
circumstances. There are reports of its successful use in primaiy pulmonary 
hypertension (Pepe-Zaba J, 1991), respiratory failure of the newborn (The 
Neonatal Inhaled NO Study Group, 1997), persistent pulmonary hypertension of 
the newborn (Roberts JD, 1992. Roberts ID, 1997) and pulmonary hypertension 
associated with congenital heart disease (Roberts JD, 1993). In ARDS, inhaled 
NO causes selective pulmonary vasodilatation, reducing pulmonary arterial
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pressure and improving oxygenation in a proportion of cases (Rossaint R, 1993).
.However, the hypoxaemia in ARDS can be completely explained by shunting, 
hypoxic vasoconstriction being only contributory (Danztker DR, 1979). Under
ventilated regions, improving oxygenation and lowering vascular resistance. In
which diverts blood to better ventilated regions, the use of inhaled NO has been 
shown to be detrimental. In these conditions, NO appears to worsen ventilation 
perfusion mismatching and gas exchange. Indeed, this was elegantly demonstrated 
by Barbera et al who showed that in patients with COPD associated pulmonary 
hypertension, inhalation of 40 ppb of NO worsened ventilation perfusion 
mismatching (Barbera JA, 1996).
1.6.2 EFFECTS ON AIRW AY SMOOTH MUSCLE
NO is also known to act as a bronchodilator by increasing the soluble guanylyl 
cyclase activity, increasing the cGMP and relaxing aiiivays smooth muscle 
(Gruetter CA, 1989). Certainly in anesthetized rabbits, relatively high 
concentrations o f inhaled NO reduced the bronchoconstrictor effect of nebulised 
methacholine (Hogman M, 1993a). In vitro, Gruetter et al demonstrated that 
carbachol-contracted proximal aiiways had greater relaxation to nitroglycerin and 
nitroprusside (NO donors) than did distal aimays (Gruetter CA, 1989). However, 
dissolved NO is much less potent in mediating the relaxation of bovine trachealis
47
such conditions, inhaled NO preferentially vasodilates arterioles supplying
■I
other pulmonaiy conditions where shunt is less significant and the preservation of 
adequate gas exchange is dependent on the integrity of hypoxic vasoconstriction
I
muscle compared to endothelium denuded bovine pulmonaiy arteiy. The potency 
of NO species in relaxing smooth muscle varies considerably with the oxidation 
state of the molecule as well as with the type and epithelial integrity of the airway. 
In both guinea pig and human aiiivays, nitroso-thiols are two logs more potent 
than nitrite in relaxing smooth muscle. However, these findings in animals have 
not been reflected in human studies. Inhaled NO has only been shown to be a 
partial and weak bronchodilator (Hogman M, 1993b), possibly due to the 
requirement for very high levels of NO locally.
1.6.3 NITRIC OXIDE IN AIRW AY INFLAM MATION
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There is also a large amount o f evidence to suggest that NO may function as a 
neurotransmitter o f nonadrenergic noncholinergic neiwes (Rand MJ, 1992). It is 
likely that NO is released from nerve endings itself, since the NOS I isoform but 
not other isofonns was found localised to peripheral nerves (Bredt DS, 1990). NO
accounts for approximately half o f the inhibitory (bronchodilator) NANG response 
in guinea pig trachea in vitro, modulates neurobronchoconstriction in vivo and 
appears to account for most of the bronchodilator NANG response in human
i
airways in vitro (Tucker JF, 1990. Li GG, 1991). NO dependent iNANG response 
.in human bronchi appear to be significantly diminished in previously deneiwated 
tissue (Belvisi MG, 1991).
The role of NO in the pathogenesis of airway disease has received less attention 
than its use as a pulmonaiy vasodilator. However in the last eight years, since it
i:4:
was discovered that exhaled NO levels are elevated in asthma (Kharitonov SA,
1994. Alving K, 1993) , a lot more work has been done in this area. Increased NO 
production in astlima may mediate the hyperaemia seen in these airways by virtue 
o f it vasodilator properties (Barnes PJ, 1996). It may also increase exudation of 
plasma by increasing blood flow to leaky post capillary venules, thus increasing 
airway oedema. Mucus secretion may also be enhanced directly or via an increase 
in blood flow to the submucosal glands. It has also been suggested that NO may 
amplify the eosinophilic inflammation in asthma by selective inhibition of T 
helper 1 (Thl) cells (Barnes PJ, 1995). This causes Th2 polarisation in the T 
helper cell population, promoting the production of IL5 and IgE.
Some o f these suggestions have been supported by coiTelations between clinical 
inflammatoiy parameters and exhaled NO levels in asthmatics. Jatakanon et al 
found that exhaled NO levels correlated with sputum eosinophils (Jatakanon A,
1998). Bronchial hyperresponsiveness and allergen induced asthmatic responses 
have been found to be associated with increased NO levels both in animals and 
steroid naive asthmatics (Mehta S 1997. Nijkamp FP, 1993. Dupont LJ, 1998).
Exhaled NO levels are also known to be decreased with steroid administration
;
(Kharitonov SA, 1996a. Kharitonov SA 1996b.Yates DH, 1995).
"iî.
Taken together, these findings suggest that increased NO production appears to 
contribute to airways inflammation. However, it is noteworthy that patients with 
ARDS and COPD do not appear to have elevated levels of exhaled NO (Brett SJ, 
1998. Rutgers SR, 1999) while atopic non-asthmatic subjects (Martin U, 1996)
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and those with viral upper respiratoiy tract infections also have very high levels of 
NO (Kharitonov SA, 1995). This may mean that NO production is not 
synonymous with airway inflammation per se.
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1.7 MEASURING NITRIC OXIDE IN THE EXHALED BREATH
In 1991, Gustaffson made the first measurement o f NO in exhaled breath of 
rabbits and humans and observed that administration of L-NMMA intravenously 
decreased NO levels (Gustaffson LE, 1991), Two independent groups then 
measured NO in exhaled breath of asthmatics and found this to be elevated 
(Kharitonov SA, 1994. Alving K, 1993). This discovery has excited many to the 
possibility o f using exhaled NO as a non invasive measure of airway 
inflammation.
The measurement of nitric oxide levels in the breath is based on the 
chemiluminescence principle where NO reacts with ozone to produce nitrogen 
dioxide. The nitrogen dioxide molecule exists at a higher energy level and 
spontaneously degrades to N and Oj, emitting a photon while doing so. The 
quantity of photons is directly proportional to the amount of NO and this energy 
is converted into an electronic signal. NO levels can be measured as volume per 
volume of exhaled air (ppb) or NO output (V^o) in ml/min.
Not long after this discovery, it became apparent that there were many problems
:ir
associated with the teclmique of exhaled NO measurement. The first and most 
important finding was that NO levels in the nose were at least 100 times higher 
than that in the lower airways (Lundberg JON, 1994). NOS II was found to be 
constitutively expressed in the paranasal sinuses of normal subjects (Lundberg
■JON, 1995) and it was suggested that these high levels may be responsible for the
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sterility of these sites. Auto inhalation of nitric oxide may also contribute to the 
innate host defense mechanisms in the lower aiiways. However, it meant that 
levels measured at the mouth may not reflect those produced in the lower airways.
The methods of measuring exhaled NO between 1991 and 1996 were also 
complicated by different techniques used by different research groups (Massaro 
AF, 1995. Alving K, 1993. Kharitonov SA, 1994. Borland C, 1993. Robbins RA, 
1996. Schedin U, 1993). The main difference involved sampling from mixed 
expired air (i.e. collection o f exhaled air over a defined period into a bag) or fi.*om 
a single exhalation. In addition, some workers asked subjects to inhale NO free air 
before collecting their expirate while others do not. One other major confounding 
factor was noted in 1997 when it was found that the rate o f exhalation 
significantly affected NO levels (SilkoffP, 1997).
Exhaled NO levels before 1996 were obtained using methodology that did not 
exclude contribution fi'om upper airways. Therefore, values in early papers were 
grossly elevated (compared to papers in subsequent years). This MD research 
project was started in 1996 and the first remit of the project was to improve and 
optimise the method of exhaled NO measurement. In 1996, Kliaritonov and 
Barnes developed a method of excluding nasal contamination of the lower 
airways air by employing a constant mouth pressure during a single exhalation 
(Kharitonov SA, 1997). This was shown to create a back pressure sufficient to
raise the soft palate, sealing off the nasopharygeal cavity during exhalation, thus
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preventing mixing o f the upper and lower airways air. I adopted the technique and 
further validated and optimised its use.
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1.8 CYSTIC FIBROSIS
Cystic fibrosis (OF) is an autosomal recessive disease caused by mutations in the 
gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) 
protein (Tsui LC, 1995). It is the commonest inherited disease, affecting 1 in 2500 
live Caucasian births. Median survival now approaches 31 years for men and 28.3 
years for women (Rosentein BJ, 1998). The identification of the CFTR gene in 
1989 combined with extensive physiological, microbiological and biochemical 
studies have provided a substantially greater understanding o f the cellular and 
moleculai* biology underlying CF.
In clinical terms, CF is a multisystem disease, characterised by abnormal 
epithelial secretions. It is manifested in the lungs by obstmction and relentless 
damage to the airways with recunent infection culminating in bronchiectasis, 
fibrosis and respiratory failure. In the gastrointestinal tract, exocrine pancreatic 
insufficiency leads to impaired digestion, recurrent subclinical pancreatitis and 
subsequently type 2 diabetes mellitus. Newborns often present with bowel 
obstruction in the form of meconium ileus and in adult patients, a similar 
syndrome o f obstruction (distal intestinal obstruction syndrome) can occur. A 
subset of patients develop focal biliary cirrhosis or multilobular cirrhosis which 
may be further complicated by portal hypertension. Male patients are infertile due 
to the absence of vas deferens, thought to be secondaiy to a developmental 
dysregulation of the Wolfian duct caused by the defective CFTR gene. The major
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cause o f morbidity arises from complications of lung disease which is the cause of 
death in more than 95% of CF patients.
1.8.1 PATHOPHYSIOLOGY OF CYSTIC FIBROSIS
The CFTR gene encodes for a protein (CFTR protein) which functions as a cAMP 
regulated chloride channel in the apical membrane of epithelial cells (Tsui LC, 
1995). A normal CFTR gene downregulates the epithelial amiloride sensitive 
sodium channel (Kunzelmami K, 1997) and upregulates the outwardly rectifying 
chloride channels (Schwiebert EM, 1995). Therefore, mutations of the CFTR gene 
not only dismpt the CFTR ion channel but also interfere with its regulation of 
other ion channels.
Among the greater than 600 mutations now registered by the CF Genetics 
Consortium, the ÔF508 mutation is present on about 70% of abnoimal CF 
chi’omosomes. The 8F508 is a biosynthetic trafficking defect in which the mutant 
protein is retained in the endoplasmic reticulum and degraded by a proteasome 
dependent pathway (Ward CL, Cell 1995). In vitro studies suggest that the mutant 
chloride channel has a reduced but measurable open time (Dmmm ML, 1991. 
Welsh MJ, 1993). Reduction or elimination of cAMP mediated chloride transport 
through the CFTR chamiel is traditionally thought to reduce the chloride and 
water secretion into the airway lumen and to cause hyperabsorption o f sodium and 
water from the lumen, producing dehydrated and viscous secretions. However, 
Smith et al have proposed that airways surface fluid in CF contains increased
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concentration of sodium and chloride ions consistent with a decrease in 
absorption of ions (Smith JJ, 1996). These data were obtained from in vitro 
studies and at present the salt content of airway surface fluid in CF patients 
remains an intensely debated subject.
Salt concentration in the aii'way lining fluid is important because defensins, a 
group of naturally occurring peptides with antimicrobial activity are known to be 
salt sensitive and potentially inactivated by higher salt concentration. Several 
genes in human encoding for these proteins, including p defensin 1  and tracheal 
antimicrobial peptide have recently been identified (Goldman MJ, 1997). 
Inactivation of these defensins by higher concentrations of salt might explain why 
CF airways become clrronically colonised with bacterial pathogens such as P. 
aeruginosa.
Other factors also make substantial contribution to the pathogenesis of CF airway 
disease. Defective acidification of intracellular organelles with secondary 
alteration o f glycoprotein (Barasch J, 1991), changes in normal endocytosis and 
exocytosis (Bradbury NA, 1992), abnoimal functioning of submucosal glands and 
sulfation of high molecular weight glycoconjugates have all been shown to be 
significant factors (Engelhard! JF, 1992). The CFTR protein itself may also play 
an important role in bacterial defences. Epithelial internalisation o f P. aeruginosa, 
a process important in defence against this bacterium is thought to be defective in 
epithelial cells with the mutant CFTR (Pier GB, 1996).
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There is also evidence that inflammation is present in neonatal aii*ways, even 
before the onset o f infection and that the CFTR gene defect may cause 
upregulation o f cytokine gene expression (Khan TZ, 1995). An interesting paper 
reported the prevention o f CF in transgenic mice after in utero gene replacement 
(Larson JE, 1997). Although the results were preliminary and intriguing questions 
remain unanswered (e.g. what is the mechanism for this effect), the finding 
suggests that the CFTR gene is involved in the normal development of the foetus 
and its defect may result in effects which are predetermined in utero.
1,8.2 DIAGNOSIS OF CYSTIC FIBROSIS
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In most cases the diagnosis of CF is considered when one or more typical clinical
features are present and then confiimed by a finding of more than 60 mmol/ 1
ichloride in sweat by quantitative pilocarpine iontophoresis (Stem RC, 1997). The 
ability to detect CF mutations and to measure bioelectric properties (Knowles MR,
1995) across the nasal epithelium have greatly expanded the identification of 
clinical variation in CF. In 2% of patients there is an atypical phenotype which 
consists o f chronic sino-pulmonaiy disease, pancreatic insufficiency and 
borderline (40-60 mmol/1) or normal (<40 mmol/1) sweat chloride concentrations.
These are thought to be secondary to milder mutations of the CFTR gene which
,retain a partially functioning and appropriately localised CFTR protein (Rosentein 
BJ, 1998).
Neonatal diagnosis by prenatal screening programmes are available in most 
developed and Western countries. In utero diagnosis of CF, based on the detection 
of two CF mutations in the foetus by chronic villus sampling or amniocentesis is 
also available.
1.8.3 M ANAGEM ENT
Most o f the morbidity and mortality in CF is attributable to chronic pulmonary 
disease. Chronic infection of the airways with Staphylococcus aureus, 
Haemophilus influenzae and Pseudomonas aeruginosa is typical (Fitzsimmon FC, 
1993). Other pathogens such as Burkholderia cepacia, Stenotrophomonas 
maltophilia, B gladioli, Aspergillus fumigatus and non tuberculous mycobacteria 
are particularly problematic in some patients. Progressive decline in pulmonary 
function is due to a viscious cycle of airway obstruction, infection and 
inflammation. Aii'way inflammation plays a pivotal role as evidenced by raised 
levels o f free DNA, IL 8 , fi*ee neutrophil elastase and neutrophils in the 
bronchoalveolar lavage fluid (Konstan MW, 1994).
The goals of therapy are to improve nutritional status, prevent or slow decline in 
pulmonary function and encourage a reasonable quality o f life. This is best 
managed by a multidisciplinary team who can provide continuity o f care over an 
extended period. Patients are encourage to maintain an unrestricted high fat, high 
caloric diet with liberal salt intake and vitamin and mineral supplements.
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Pancreatic enzyme replacement for those requiring this usually takes the foim of 
enteric coated tablets.
The approaches to the prevention of pulmonary deterioration include aggressive 
antibiotic regimens, airway clearance techniques, anti inflammatory agents, 
regular exercise, mucoactive agent and treatment of airway reactivity. Bilateral 
lung or heart lung transplant is the ultimate treatment for end stage lung disease. 
Recent results indicate 73% survival at one year, 63% at two and 57% at three 
years post transplant (Tmlock EP, 1997). Bilateral lobar transplantation from 
living donors is offered at some centres as an alternative to cadaveric 
transplantation, with similar results. This approach is still ethically controversial 
but is partly di'iven by the lack of suitable donor organs. Some patients may 
benefit from non-invasive assisted ventilation while awaiting transplant.
The importance o f aggressive antimicrobial treatment is generally agreed but how 
to do this is not. Potential approaches include short tenn treatment o f acute 
exacerbations with oral, aerosol or intravenous antibiotics, and long teim 
treatment with oral or aerosol antibiotics and long tenn treatment with quarterly 
courses of intravenous antibiotics. The efficacy and safety of high dose 
aerosolised Tobramycin are well established (Ramsey BW, 1993). It is usually 
used as a maintenance therapy in patients with cln'onically infected P. aeruginosa 
to slow the progression of lung disease and to increase the interval between 
exacerbations. In some centres, it is being used after the initial isolation of P. 
aeruginosa to delay chronic infection. Long term anti staphylococcal therapy early
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in life before the onset of pseudomonas infection is also been employed in some 
centres (Weaver LT, 1994). Use o f domase-alfa, an agent which depolymerises 
DNA and decreases the viscosity of airway mucous has been shown to reduce the 
frequency of pulmonary exacerbations and delay pulmonary decline in a subset of 
patients (Fuchs HJ, 1994).
Approaches to suppression o f aii'way inflammation include oral alternate day 
corticosteroids, clironic use of inhaled steroids (Oermann CM 1999) and chronic 
high dose ibuprofen (Konstan MW, 1995).
1.8.3.1 NEW  THERAPIES
Two intensely investigated new therapeutic strategies are gene therapy and more 
recently, ‘protein repair therapy’.
Better understanding of the different types of CFTR mutations has led to new 
therapeutic approaches. Defects in CFTR production, folding, trafficking, or 
chloride conduction can be addressed by strategies organised in a genotype- 
specific way. Class I mutations decrease production of CFTR protein. About 5% 
of all mutations involve premature stop codons that lead to early termination of 
CFTR mRNA. These mRNAs are unstable and are never translated into protein. 
Certain aminoglycoside antibiotics (e.g. gentamicin) may suppress these 
‘nonsense’ mutations and restore frill length CFTR mRNA protein to the cell 
(Howard M, 1996).
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Class II trafficking mutations o f which 6F508 is the most common are defects 
with respect to structural assembly in the endoplasmic reticulum and are not 
efficiently glycosylated or transported to the cell surface. This protein retains 
partial chloride channel activity and is transported to the cell surface after 
treatment with chemical chaperones like glycerol These are thought to facilitate 
protein folding and stabilise protein structiue, thereby promoting processing and
-
trafficking to the cell surface (Brown CR, 1997). An alternative to these 
chaperones is phenylbutyrate, an oral analogue of butyrate that appears to regulate 
the expression of many genes including those for CFTR, y globulin and those 
involved in cell differentiation (Pemne SF, 1993). It has been shown to promote 
the trafficking of the 5F508 protein in vitro and in vivo.
Class III mutations are completely defective with respect to regulation and 
.activation o f chloride channel activity whereas class IV mutations (R117H) have 
partial response to cAMP mediated stimulation. Thi'ee agents are being 
investigated for CFTR activation in these genotypes. Milrinone is a 
phosphodiesterase inhibitor that improves chloride conductance (Kelley TJ, 
1997). Genistein, a tyrosine kinase inhibitor that appears to augments the chloride 
channel via inhibition of protein phosphatase (Illek B, 1995) and CPX 
(cyclophenyl-1,3-dipropylxanthine) a xanthine adenosine receptor antagonist that 
specifically activates the ÔF508 chloride channel (Guay-Broder C, 1995).
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1.8.3.2.GENE THERAPY IN CYSTIC FIBROSIS
The option o f gene replacement therapy in CF is attractive since, theoretically, 
with one therapeutic inteiwention the myriad downstream effects of a mutant gene 
can be corrected. This is particularly true for CF since it is a monogenic disease 
and the target organ, the lung, is readily accessible. Vectors can be applied 
directly to airway epithelia without the need to haiwest the target cells, modify 
them genetically and return them to the body. Rapid progress towards gene 
replacement has been made since the identification of the gene resulting in the 
first Phase 1 clinical trial in the nasal epithelium in 1991 (Zabner J, 1993). The 
most studied vectors are adenovirus, adeno-associated viruses and liposomes.
Recombinant adenoviral vectors are derived fi om human serotypes 2 and 5 of the 
group C adenovims family. They are not oncogenic and the genome can 
accommodate 36 kb of double stranded DNA. This large capacity allows removal 
o f selected genes involved in viral replication and replacement with the 
therapeutic promoter-cDNA constmct. Gene delivery by adenovirus vectors in 
animal models has been limited by low vector entry rates in intact, non inflamed 
tissue and in CF patients by rapid induction of an inflammatory response to both 
viral vector and /or modified cells (Ho LP, 1998). Efforts to modify the virus/cell 
interaction to improve targeting in the lung, to allow repeat dosing, and/or to 
transiently manipulate the immune system to enhance gene expression are likely 
to dominate the field in the next few years.
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AAV is a veiy small single stranded DNA defective parvovirus which cannot
t
1
reproduce itself unless provided with a ‘helper’ virus like the herpes simplex
.virus. An AAV vector is fonned by replacing the two endogenous viral genes with 
the promoter and/or cDNA of choice (Curiel DT, 1996). Advantages include the 
non pathogenic and non tumorigenic character of the wild type virus, the 
preservation of infectivity after both the viral genes are removed and the potential 
for site specific integration in the host genome which would tend to increase the 
persistence o f the transduced gene (Flotte TR, 1995). Disadvantages are the lower 
efficiency when compared to adenoviral vectors and the limited capacity for large 
exogenous DNA sequences.
I
,Synthetic non viral vectors of which cationic liposomes and cationic polymers are
the major examples have advantages over viral vectors with respect to toxicity and
immunogenicity (Gao X, 1995). They can deliver large DNA sequences and are
easy to produce in large quantities. Gene transfer to the nasal epithelium of CF 
.patients is associated with improvements in chloride transport but the effects are 
transient and repeat dosing will be necessary for sustained effect.
The march of gene therapy into human trials has been faster and more aggressive 
than anticipated. At least 11 trials (Ho LP, 1998) have been completed involving 
both viral and liposomal delivery to the nose and the lungs since the cloning of the 
gene 9 years ago. A large amount of work is currently being done on improving 
the vector and understanding the bamers to gene transfer and persistence. The 
outlook is optimistic but clinical trials have proven that many areas require further
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work. One of these is the ability to detect, accurately, correction of the basic 
genetic defect and its downstream clinical improvement. Most available clinical 
measurements o f efficacy have significant limitations - trans-epithelial potential 
difference measurements, fluorescence imaging of chloride channels and biopsies 
for inflammatory cell numbers are limited by information derived from only a 
small and possibly non representative area. Lung function tests on the other hand 
are too crude and insensitive to detect small changes in cellular activity and 
subclinical improvements. It was with this need for a sensitive, reproducible and 
non invasive method o f measuring pulmonaiy inflammation in mind that this MD 
project was originally designed.
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1.9 AIMS AND OUTLINE OF THESIS.
At the start o f this MD project (1996), the aim was to examine the use of exhaled 
nitric oxide as a possible marker of airway inflammation and clinical severity in 
patients with cystic fibrosis. It was intended then, that, this measurement may be 
developed to a standard where it could be used as a clinical measure of efficacy 
and safety in the CF gene therapy trial in the lungs.
The expression of inducible NOS was known to be increased by proinflammatory 
cytokines (Robbins RA, 1994) and levels of NO have been reported to be 
increased in the exhaled air of astlmiatics (Alving K, 1993. Kharitonov SA, 1994) 
and bronchiectasis (Kharitonov SA, 1995). In addition, NOS activity as measured 
by ability to convert L-arginine to L-citmlline have been found to be increased in 
CF hmg homogenate (Belvisi M, 1995). As discussed, patients with CF have 
gross pulmonary inflammation. Therefore, I hypothesised that NOS II expression 
in the persistently inflamed airway epithelial and inflammatory cells in cystic 
fibrosis patients would be increased. This would be manifested as increased NO 
levels in the exhaled air which may reflect severity of airways inflammation in 
these subjects.
However, the first major finding from the project was that exhaled NO was not 
raised in patients with CF in contrast to astlimatics. This was a novel and an 
unexpected finding at that time and the aims of the study were then redirected
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towards examining the possible explanations for this. Broadly, this may be due to
fibrosis, the following studies were then conducted:
two reasons: firstly NO production is increased but not detectable in the exhaled 
breath. This could be due to removal of gaseous NO by reaction with other free
■ ",radicals or reactive oxygen species in chronically inflamed airways. Excess
secretions could also prevent diffusion of the gaseous molecule into the lumen.
Secondly, NO may be produced in lower quantities secondary to a defect in 
.expression of the nitric oxide synthase gene which in turn may be related to the 
CFTR mutation, the chronic inflammatory state or lack of substrate (l-arginine).
Thus, the thesis first reports the development of exhaled NO as a method for 
measuring airways NO. Then it reports the finding of exhaled NO in CF patients 
with comparison to asthmatics and healthy volunteers. In order to explore some of
the possible reasons for the observation that exhaled NO is not elevated in cystic
1 ) exhaled NO levels were examined in patients with bronchiectasis, a group with 
suppurative lung disease similar to CF to examine if excess secretion and chronic
' I
inflammation may be a cause for the lack of exhaled NO
2) molecular evidence of NOS II expression in CF epithelial cells lines (the 
purported cells responsible for elevated NO in asthmatics) and primaiy CF nasal 
epithelial cell cultures was examined
,3) hydrogen peroxide levels in expired breath were measured to examine if levels of 
another volatile reactive species is increased
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4) a different method of NO measurement was developed (nitrite in expired 
breath) and used in CF patients to explore if NO production may be elevated but 
not detected as gaseous NO in exhaled breath.
1.10 ETHICAL APPROVAL
There was ethical approval from the Lothian Ethics Committee for all studies 
involving patients. All subject gave informed consent.
I
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CHAPTER 2 
DEVELOPING THE M ETHODOLOGY OF M EASURING NITRIC  
OXIDE IN THE EXHALED BREATH  
2.1 BACKGROUND
The history o f exhaled NO measurement has already been discussed in chapter 
1.7. At the start o f this MD project (1996), my first aim was to establish a method 
of measuring exhaled NO levels which was sensitive, reproducible and excluded 
nasal air contamination. At that time, various methods of measurement were being 
used and there was wide variation in reported values of exhaled NO in normal and 
disease states (table 3). The methods available then were single breath collection, 
mixed exhaled air sampling from a bag and mean values over a few tidal breaths. I 
chose a new technique which appeared to have the capacity to eliminate nasal air 
contamination. My first priorities were to determine a representative point from 
the exhaled NO profile, examine other possible confounding factors and establish 
the reproducibility of this method in our laboratory.
2.2 THE EQUIPM ENT
The nitric oxide analyser was purchased from Logan Research Limited 
(Rochester, U.K.). It is a rapid and highly sensitive chemiluminescence analyser 
(model LR 2000, version 2,2) and specified by the company to have a resolution 
of 0.3 ppb and a 95% response time (time between detecting zero amount o f NO
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and 95% of delivered NO) o f 0.4 seconds. It is a single breath analyser connected 
to a dedicated personal computer and measures NO and CO^ levels simultaneously 
in each exhaled breath. These levels are displayed on the screen during each 
exhalation. There is a short Tag time’ between detection and display on the 
computer screen of 1.8 seconds for NO and 1.4 seconds for CO^. The value at any 
point o f the NO exhalation profile is the average of 50 NO levels measured at
0.04 second intervals. The screen also displays the mouth pressure and exhalation 
flow rate (figure 2 ),
The amount o f NO (vohvol) in exhaled air is derived from the number of photons 
that are released from the degradation of NOj after NO in the exhaled air reacts 
with ozone (described in chapter 1.7). The generation of ozone and its reaction 
with NO is a vital part o f the analysis. This takes place in a vacuum which is 
created by a pump in the analyser. Accurate operation of the analyser is crucially 
dependent on this vacuum. Carbon dioxide is analysed using a single beam 
infrared analyser incorporated in the machine.
Schematic illustration o f this analyser is shown in figure 3.
An important part of the equipment is the exhalation circuit. This comprises an 
internal flow resistor which provides a small positive pressure at the mouth (5-20 
cm HgO). There is a visual (LED) feedback panel which tells the subject how 
much mouth pressure is being generated during the exhalation and the subject is 
coached during the procedure to keep this mouth pressure constant at 5 cm H 2 O.
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—Theoretically, this creates a back pressure in the oral cavity during exhalation
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which results in the elevation of the soft palate. This in turn ‘seals o ff  the 
nasopharyngeal area and eliminates mixing of nasal air with lower airways air.
This theory was subsequently confirmed by a study published in 1997 where
7-radioactively tagged argon gas flushed into the nasal cavity was shown to be 
undetectable in the exhaled air using this method (Kharitonov SA, 1997).
;
Air from each exhalation is extracted for analysis at 250 ml/min. However, this is 
affected by how fast the subject exhales, which in turn correlates directly with 
mouth pressure (although not in a linear fashion). Therefore, during each 
exhalation, the mouth pressure is the most important part o f the maneouvre and 
constancy o f all other parameters depends on keeping the mouth pressure 
constant.
The analyser is calibrated every third day of use with 103 ppb NO/N 2  gas mixture 
(BOC, Kent). The mouth pressure and flow rate are calibrated monthly using a 
hand held pressure manometer and a flow rotameter.
2.3 STUDIES
Thi'ee studies were performed to validate the exhaled NO method.
2.3.1 STUDY 1 - POSSIBLE CONFOUNDING FACTORS IN EXHALED  
NITRIC OXIDE MEASUREM ENTS
AIMS
To examine the effect of the following possible confounding factors on exhaled 
NO levels:
i. ambient NO levels
ii. mouth pressure
iii. breath holding
2.3 .I.I. AM BIENT NITRIC OXIDE LEVELS 
METHODS
Since ambient NO levels in Edinburgh vaiy between 0.4 ppb and 50 ppb, it was 
important to examine if this affected the exhaled NO levels. This was studied in 
two ways. Firstly, in nomial non smoking subjects (n=3), exhaled NO levels were 
measured after inhaling atmospheric air (with ambient NO level o f 0.4 ppb) and 
air containing 80 ppb of NO. Increased levels o f NO in the inspired breath were
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generated by adding NO gas to the inspired air. A circuit to provide the coiTect 
admixture of NO in air was designed to allow compressed air to pass at 20 1/min 
through a carbon NO scrubber. This was passed into a T-piece comiected to a 
tubing fed with 50 ppm NO at a flow rate of 0.04 1/min. The net admixture 
produced air containing about 75-85 ppb at the tube joining the T-piece. The 
absolute value was checked by the NO analyser and shown to be 80 ppb. 
Secondly, exhaled NO levels were measured (in 3 normal non smoking subjects) 
on four days with different levels o f ambient NO- 0 . 2  ppb, 5 ppb, 30,5 ppb and 50
ppb.
RESULTS
During exhalation, the plateau NO level, in contrast to the peak NO level, did not 
differ whether subjects inhaled 0.4 ppb of ambient NO or inspired air containing 
80 ppb NO (table 4).
In keeping with this finding, there was no significant difference in end expiratory 
(plateau) exhaled NO levels in all three subjects when inhaling different ambient 
levels (table 5). However it was noteworthy that the peak and early levels in the 
exhalation profile were markedly affected by the ambient levels of NO. Therefore, 
if  the plateau levels were not attained as in subjects with smaller vital capacity 
(e.g. in diseased lungs), exhaled NO levels may not be accurate.
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2.3.I.2. MOUTH PRESSURE
METHODS
Although, the manufacturer had recommended a mouth pressure of 5 cmH^O, I 
was concerned that some patients may not be able to maintain this specific level. 
Therefore, I examined if changes in mouth pressure affected exhaled NO levels 
and if  there was a range that could be allowed for patients who experienced 
difficulties with maintaining the specific value of 5 cmH^O. Three nomial, non­
smoking subjects were recmited. In each, mouth pressure and (consequently flow 
rate) were varied during exhalation (2, 5 and 10 cm HjO) and exhaled NO levels 
recorded at the end (plateau) of the exhalation profile.
RESULTS
There was no significant difference between NO levels taken at 5 and 10 cmHgO 
but levels at 2 cm H^O were significantly higher (table 6 ). In addition, NO levels 
taken at 2 cmHgO mouth pressure were highly variable. This suggested that 5 cm 
HjO may be the threshold of mouth pressure required to ensure adequate sealing 
off o f the nasopharyngeal ai*ea by the soft palate. Pressures lower than that may 
allow leakage o f nasal air and may explain the variability in NO levels.
73
oo\cn
o CNod
oo
od Ood oood
oo oo
ru
"O
(N Oud
OrH
2.3.I.3. BREATH HOLDING
METHODS
At this point of the study there were reports using other methods (which did not 
exclude nasal air contamination) that suggested that breath holding affected NO 
levels. The same subjects (n=3) were asked to exhale without breath holding and 
after 10 and 20 seconds o f breath hold. This was repeated with subjects exhaling 
immediately after 2  minutes of continuous conversation.
RESULTS
For breath holding, there was a clear increase of peak levels with increased breath 
hold time but end expiratory levels were not affected (Table 7). Talking before 
measurement also affected the peak NO levels. This was likely to be secondaiy to 
inadvertent breath holding during conversation.
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2.3.2. STUDY 2 - REPRESENTATIVE NITRIC OXIDE LEVEL ON 
EXHALATION PROFILE
AIM
To determine the most appropriate point on the NO exhalation profile to record the 
representative NO level for a subject.
M ETHODS
The single breath profile is characterised by a small peak and then a longer plateau 
(figure 2). To determine the agreement at different parts of the profile, NO levels 
were taken at the:
a) end expiratory point, (NOe,, ,^ figure 2) defined as the point within the last 3 
seconds at the end of expiration (coiresponding to the near plateau level of the CO^ 
profile)
b) plateau point (NOp,at), defined as any point after the first thi'ee seconds of 
achieving a plateau
c) peak level (NOp^^J - the highest NO level in a single exhalation 
These points were chosen because NOg,,^, NOpi^  ^ are likely to represent the values 
from the end of expirate and hence the lowest part of the airways. These would be 
the ideal representative levels. However, the most appropriate point on the plateau 
phase o f the profile was not known and the study examined if  there was any 
significant difference between values near the beginning of the plateau compared to
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the end of an expiration. was chosen as a comparison because this was one
of the standard methods of measurement at that stage of exhaled NO research.
Three normal non-smoking subjects with no clinical evidence of upper respiratory 
tract infections were recruited for these studies. Levels were taken 7 times 
sequentially on 2 different days. Subjects were seated upright and asked to exhale 
slowly from total lung capacity following a full inspiration. Subjects wore nose 
clips and maintained a mouth pressure o f 5 cmHjO. The procedure was repeated to 
obtain seven technically acceptable manoeuvres (based on manoeuvres perfoimed 
without breath holding or interruption e.g. from coughing and maintenance of 
constant mouth pressure of 5 cmHgO for at least 80% of the exhalation profile). 
Levels were recorded at points of interest (NOpg^ k , NOg„j and NOpi^ t ) on each 
exhalation. ANOVA was then perfonned between these points.
RESULTS
There was no significant difference between levels taken at a point after 3 seconds 
of plateau had been achieved (NOpj t^ ) and at the end of the plateau (NOg^J, 
suggesting that levels taken at any point after the first 3 seconds of achieving a 
plateau are representative o f the single exhalation profile. Using paii*wise multiple 
comparison in one way analysis of variance (ANOVA), NOpga^  was found to be 
significantly higher than NOpj t^ and NOg„d. NOp^ ^^  was significantly higher than 
NOpjat. The peak value was also more variable within each subject compared to 
plateau levels and sensitive to even short periods of breath holding.
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All values are shown in table 8 .
Other observations
During the course o f these preliminary experiments, it was noticed that 
condensation build-up was a frequent occurrence in the exhalation arm of the 
setup. Since NO is a highly reactive molecule, I examined if the presence of water 
in the path of the exhaled air affected the NO levels. This was done by measuring 
NO levels before and after drying the tubing with high flow oxygen flushing. 
There was no significant difference in the NO levels before and after drying the 
tubing; there was a drift towards lower levels with the presence of condensate.
FINAL M ETHODOLOGY FOR EXHALED NO MEASUREM ENT
The final method adopted for the measurements in the project incorporated the
following features:
1. The NO analyser is set at an extraction flow rate of 250 ml/min.
2. The ambient nitric oxide level is measmed by allowing the analyser to sample 
room air over 30 seconds. If the background levels were high (>10 ppb) and 
the subject is unable to achieve a substantive plateau (>5 seconds) in the 
exhalation profile, the procedure is abandoned as an accurate level would not 
be obtained.
3. All tubing in the collection system is ensured to be free from condensation.
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4. The subject is asked to sit upright facing the NO analyser. The procedure is 
explained to the subject and the subject is asked to breathe normally and 
discouraged from talking just before the procedure.
5. The subject inspires to total lung capacity and exhales immediately into the 
mouthpiece while watching the visual biofeedback. Mouth pressure is kept 
constant at 5 cm H^O. If  there are difficulties in maintaining this pressure, 
subjects are asked to exhale over the target (> 5 cmH^O) rather than to allow 
the pressure to fall below 5 cmH^O.
6 . The subject exhales until the NO profile reaches a plateau and the CO 2  profile 
a near plateau (it is not physiologically possible to reach a complete plateau 
for CO 2 ). A plateau is defined as a horizontal line at an angle of 25° or less, 
for more than 5 seconds. This is usually visually discernible.
7. This is repeated three times and the representative value from each profile is 
taken from the end expiratory point. The mean of three levels is taken as a 
representative value for that subject.
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2.3.3. STUDY 3 - REPRODUCIBILITY OF FINAL METHOD
AIM
To examine the reproducibility of the final method.
M ETHODS
NO plateau levels were obtained from seven subjects on three to six occasions 
separated by at least a day. All subjects were healthy non-smokers with no 
respiratory symptoms. To test reproducibility of plateau NO measurements, 
Bartlett’s Test for equality of variance within each patient was first applied. 
Analysis of variance was then used to deteimine variance and thus global standard 
deviation.
RESULTS
Individual results are shown in table 9.
Equality of variance within each patient tested by Bartlett’s test showed no 
significant difference between patients. ANOVA for seven subjects with repeated 
measurements (between 3-6 times) of exhaled NO gave a pooled standard 
deviation of 0.84 ppb, and a coefficient o f variation = 0.24. The 95% confidence 
interval for any measurement of NO was thus ±1.72 ppb.
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2.4 DISCUSSION
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The accurate measurement of nitric oxide production in the lower airways is 
.crucial to the examination of its role in the aiiways. In order to derive correct 
conclusions it would be important to know what exhaled nitric oxide represents -  
does it reflect lower airways NO production, if  so how much of it does, what is the 
contribution o f different parts o f the aiiivays to the exhaled values and what
factors affect these measurements?
I
In 1996, Massaro and co workers demonstrated that exhaled NO levels were 
indicative o f lower airways NO production when they showed that bronchoscopic 
measurements of NO in the lower airways o f asthmatics revealed levels that were 
elevated and comparable to those measured in the exhaled breath (Massaro AF, 
1996). Subsequently, Gabay et al (Gabay E, 1998) using an identical analyser to 
the one used in this study, showed that there was a good agreement between 
bronchoscopically measiued levels in the lower airways and that at the end 
expiratory levels in exhaled air. They also confirmed my findings on the 
repeatability of NO levels at the end expiratory phase of the exhalation profile.
J;
The studies above demonstrated that if  all criteria for accurate measurements are
#followed (as specified under ‘Final methodology’), then this method is a 
reproducible way of measuring NO production from the lower airways. The only 
caveat was that on days when the ambient NO levels are high (>10 ppb)
.... ■.
measurements can only be made in subjects who are able to exhale long enough to 
obtain a plateau level. This may be a significant limitation in patients with small
vital capacity like those with cystic fibrosis patients and severe bronchiectasis. 
Fortunately, in Edinburgh, high levels of background NO were veiy uncommon (< 
5% of a month, observed during the preliminary studies). In other cities e.g. 
London, where levels in excess of 50 ppb are common place, NO free inspired air 
may be needed.
The finding that high inhaled NO levels did not affect exhaled end expiratory 
levels o f NO was interesting (table 4). Although my aim was to detemiine whether 
ambient NO affected expired lower respiratory tract NO, the results also suggested 
that gaseous NO appears highly labile within the aimays. Within the duration of a 
single inhalation and exhalation (approximately 10-15 seconds) it has either 
diffused into the pulmonaiy circulation or metabolised to other products. The most 
likely explanation is that inhaled NO reaches the alveoli and is immediately 
absorbed into the pulmonary circulation (Hyde RE, 1997). The first phase of the 
exhaled breath represents air from anatomical and physiological dead space and 
reflects high NO levels that are still present this part of the airways. The last phase 
of the expirate reflects NO levels horn the lower parts of the airways. Results 
from this experiment suggest two points - firstly that NO produced in the vicinity 
of the alveoli is likely to be reabsorbed very quickly and not reflected in the 
expirate. Secondly what is detected at the end of an expired breath probably 
represents high and continuously produced NO from the airways (rather than 
parenchyma). This method may, therefore, not be able to detect lower (but still 
elevated) levels of NO generation.
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At present, it is unclear where exhaled NO originates. It is likely to represent 
luminal production since NO in the circulation is tightly bound to the haem 
component o f haemoglobin (Stamler IS, 1988) and does not contributed to the 
gaseous pool o f nitric oxide. However, recent evidence suggest that in disease 
states the decrease in pH at the air-fluid interface in alveoli encourages the 
dissociation o f NO-haem complexes and under such conditions, luminal NO may 
be increased by NO from the pulmonary circulation (Gow AJ, 1998). Also, the 
cellular source o f NO production remains unclear. NO is produced by almost all 
cell types within the airways (Nathan C, 1994). It is likely that airway epithelia by 
virtue of size and the number of NO producing units may contribute most to an 
increase in levels. It is also unknown how much each isoform of NOS contributes 
to the level o f exhaled NO, In normal states, nNOS is thought to contribute about 
30% of exhaled NO levels in mice. This is derived from studies comparing normal 
and nNOS knockout mice (De Sanctis GT, 1997). However, in disease states like 
asthma, it is likely that NOS II driven NO makes up most o f the increase in NO 
levels. NOS II expression in the epithelium of asthmatics have been shown to be 
increased (Hamid Q, 1993) and NO production by this enzyme is much greater 
than that from the constitutive enzymes (Vodovotz Y, 1994). No studies have 
examined the expression of the other isoforms in asthma.
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Thus the method used here carries the above unanswered questions and 
limitations. Exhaled NO levels remain a non specific marker of NO production in 
the airways.
2.5 CONCLUSION
Exhaled NO can be measured easily and reliably provided all criteria for 
measurements are followed. The main limitation is that it is a non discriminating 
measure of NO production from the lower aiiways.
The 95% confidence inteiwal for each individual measurement is ± 1.72 ppb.
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CHAPTER 3 &
EXHALED NITRIC OXIDE LEVELS IN PATIENTS WITH CYSTIC
-FIBROSIS COMPARED TO NORMALS AND ASTHMATICS.
■Ï
3.1 INTRODUCTION
3.2 HYPOTHESIS
84
As discussed in chapter 1, expression of NOS II is increased by proinflammatory 
cytokines and LPS and patients with CF have severely inflamed aiiways. 
Therefore, it can be hypothesised that NO production is increased in this inflamed 
environment. The study examines NO levels in the exhaled breath of CF patients 
and compares this with normal controls and asthmatics.
Exhaled NO levels in patients with cystic fibrosis are increased compared to 
normal subjects and may reflect clinical severity in these patients.
I
3.3 STUDY DESIGN  
Subjects and patients
Thirty six patients with cystic fibrosis were recruited from the Scottish Adult 
Cystic Fibrosis Seiwice, Edinburgh. All except three had fully defined CF 
genotypes (the remaining three were 5F508/?). Disease severity varied widely.
with predicted FEV, ranging from 18% to 100%. Patients with concomitant 
astlima and those who were on inhaled steroids were excluded.
As a positive control, 34 patients with asthma were recruited from the respiratory 
outpatient clinic and from general practices. All patients had documented 
reversible air flow obstmction and were on inhaled pj-^gonist. 23 were on inhaled 
steroids (doses ranging from 400pg to 3200pg per day). Eleven astlimatics were 
steroid naive. The FEV, for the whole gi'oup ranged from 34% to 100% predicted. 
All patients were non smokers and clinically stable. Twenty-two healthy 
volunteers were recruited from hospital staff. These were non- smokers, had no 
respiratory tract symptoms and did not have active allergic rhinitis at time of 
sampling. The mean ages (± SD) were 32.0 (12.6), 27.1(8.6) and 45.2 (16.8) years 
for normal subjects, CF and asthma patients respectively.
In 10 CF patients ( 8  males, mean age 26.5 years), exhaled NO was also examined 
during infective pulmonary exacerbations. Levels were measured within 24 hours 
of onset of an infective exacerbation, defined as a worsening of clinical condition 
requiring intravenous antibiotics accompanied by a fall of 400 mis or 20% of 
usual FEV). All measurements were performed before or within six hours of 
commencement o f IV antibiotics. In eight of these subjects, serial exhaled NO 
measurements and lung function were recorded over seven days.
Informed consent was obtained from all subjects and the study was approved by 
Lothian Health Ethics Committee.
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M easurement of exhaled nitric oxide
Nitric oxide was measured using a sensitive chemiluminescence analyser (LR 
2000, Logan Research Ltd, Kent, U.K.) as described in Chapter 2.
3.4 STATISTICAL ANALYSES
3.5 RESULTS
Exhaled NO levels in cystic fibrosis, asthma and normal subjects.
For comparison o f NO levels between groups, Mann Whitney rank sum test was
,used since the asthmatic groups showed deviation from normal Gaussian 
distribution. CoiTelation between lung function with exhaled NO in the CF group 
was measured using Pearson’s Product Moment correlation test. For all tests, 
p<0.05 was assumed to achieve statistical significance.
NO levels in patients with CF and nonnal subjects did not differ significantly
fi'om each other. The median value in patients with CF was 4.0 ppb (interquartile
■range, 3.1) and normal subjects had a median value of 4.4 ppb (interquartile range, 
3.4) (figure 4). Patients with asthma had a significantly higher median value 
compared to all the other groups (10.4, interquartile 16.9). There was a positively
skewed distribution and a large range of values in the asthmatic population.
I
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Figure 4. Exhaled NO levels in patients with cystic fibrosis, astlnna and in nonnal 
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CS= inhaled corticosteroids. CF= cystic fibrosis.
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Correlation between lung function and exhaled NO levels in stable patients.
There was a weak but statistically significant positive correlation between exhaled 
NO and FEV, in patients with CF (r = 0.48, p < 0.05) (figure 5). Thus, patients 
with better lung function appeared to have higher exhaled NO levels. This was not 
seen in bronchiectasis or astlnna.
Infective pulmonary exacerbations and exhaled NO levels in patients with 
cystic fibrosis.
During pulmonary exacerbations exhaled NO remained within the normal range 
(figure 6 ). In 7 out o f 10 patients, the values were the same or lower than when
clinically stable. In 3 patients there was a small but insignificant rise. For eight 
patients serial exhaled NO measurements made over seven days after 
commencement of IV antibiotics showed no consistent trend with time (figure 7).
3.6 DISCUSSION
In this study, a method which excluded nasal air was used and a single exhalation 
flow rate for all subjects were employed. With this method , it was demonstrated 
that exhaled NO levels in CF and bronchiectasis were no different from that in 
normal subjects. However, in keeping with published work, high levels were 
detected in asthmatics. These findings in cystic fibrosis were supported by reports,
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îali in children, which were published around the same time. Methodological 
differences did not allow absolute comparison but all reported NO values in CF 
patients that were no different from control subjects (Lundberg JON, 1996. 
Balfour-Lynn IM, 1996. DOtsch J, 1996). In none of these studies, however, was
:nasal NO definitely excluded. In one study (DOtsch J, 1996) the response time of 
the analyser was slow, risking “contamination” from the ambient air, and indeed 
the study showed good con*elation between exhaled NO and ambient NO.
Furtheimore, levels were obtained from a collection bag containing mixed expired 
air. In the third study, patient numbers were small.
The absence o f elevated levels of NO in the exhaled breath of patients with CF has 
a number o f potential explanations. There may be a decrease in diffusion of NO
h;
across secretions of increased viscosity and volume. Alternatively, in a 
suppurative and inflamed enviromnent, the presence of reactive oxygen species in 
the vicinity of the NO production may result in chemical interaction with the 
effective removal of NO by formation, for example, o f peroxynitrite (Wink D,
1993). As discussed in chapter 1, NO has been shown to be a potent scavenger of 
reactive oxidants in the lung. Either explanation would be consistent with our 
finding that NO levels in the breath of cystic fibrosis patients correlated positively 
with lung function. Patients with mild disease would have less viscid and fewer 
secretions, and less production of reactive oxygen species.
Low NO generation in CF and bronchiectasis may have important implications for 
host defence, since low levels o f NO produced by the epithelium may result in
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decreased local bacterial killing and thus facilitate chronic bacterial colonisation 
and repeated infections.
Two other findings from the study were interesting. Firstly, in CF patients with 
infective exacerbation, levels did not change during the first 24 hours of infection 
and with follow-up over time. This could mean either that there is a failure to 
upregulate NOS II in response to infection and increased inflammatory stimuli or 
that there was an increase in NO production but this was not detected because of 
the blanket effect o f airways secretions. Secondly, patients with better lung 
function had higher NO levels. This was at odds with the theory that exhaled NO 
levels reflect aii*way inflammation. In addition to the suggestion above that 
detection of gaseous NO may be improved in those with better lung function and 
hence less viscid secretions, this also supports the possibility that down regulation 
of NOS II occurred in the airway epithelia of patients with worse lung function 
and therefore, more severe inflammation.
Although the measurement o f exhaled NO in asthmatics was not the principal 
purpose o f this study sufficient numbers were studied in this positive control 
group to observe wide variation in levels fi-om patients who were steroid naïve. In 
some patients with more severe asthma but who were on inhaled steroids, levels 
were noted to be lower. Steroids may well reduce NO levels by downregulation of 
NOS II thus explaining the observation (Kharitonov SA 1996a&b. Yates DH 
1995). This questions whether the elevated exhaled NO levels in asthma are a 
reflection of the clinical severity of astlnna, a guide to the degree of aimays
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inflammation present or a marker of balance of cytokine activities in the airways 
and NOS II regulation.
3.7 CONCLUSION
Using a method which excluded nasal air contamination and applying a standard 
exhalation rate in all our patient groups, exhaled NO levels are not elevated in the 
inflammatory aii*ways disease of CF, in contrast to asthma. This is the case even 
during pulmonary infective exacerbations. Exhaled NO is not a helpful clinical 
marker o f airways inflammation in CF.
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CHAPTER 4 
EXHALED NITRIC OXIDE LEVELS IN PATIENTS W ITH BRONCHI­
ECTASIS
4.1 INTRODUCTION
The findings from Chapter 3 suggest that the lack of increase in NO levels in CF 
compared to asthma may be due to lack of detection or lack of production of the 
gas. To explore the foimer, levels in patients with bronchiectasis were determined 
using the same methodology. Bronchiectatic patients were chosen because these 
patients have veiy similar airway pathology to CF patients. Both display damaged 
airways which allowed pooling of excess secretions, bacterial colonisation and 
recurrent infection. Aii-ways inflammation is driven by clironic bacterial presence.
4.2 HYPOTHESIS
It is hypothesized that if  exhaled NO levels in patients with CF are reduced due to 
poor gaseous diffusion into the lumen, then the same phenomenon would be 
observed in patients with bronchiectasis.
4.3 STUDY DESIGN
Patients
91
—M easurement o f exhaled nitric oxide
Nitric oxide was measured using a sensitive chemiluminescence analyser (LR 
2000, Logan Research Ltd, Kent, U.K.) as described in Chapter 2.
4.4 STATISTICAL ANALYSES
For comparison of NO levels between the two groups of patients, the Student t- 
test was used. Correlation between age and exhaled NO was measured using
Sixteen patients with bronchiectasis were recmited from the respiratory outpatient
clinic. Bronchiectasis had been diagnosed by classical chest x-ray changes in 6
.patients, by classical CT changes in 4 patients and by bronchography in 6 patients. 
In five patients, bronchiectasis was secondary to childhood bronchopneumonia, in
three to tuberculosis, one to whooping cough, two to measles and five had no
determined cause for their bronchiectasis. Six patients were on inhaled steroids. ;v:
iNone had evidence of asthma or allergic bronchopulmonary aspergillosis. Thegroup had widely varying disease severity (FEVj 32% to 91% predicted).
:,;y
Since the difference in mean age between the CF and bronchiectasis group was
necessarily large (27.1 years v 57.2), we also tested the relationship of exhaled NO 
.with age. For this, 22 non smoking, normal subjects with no evidence of active 
atopy or respiratory tract infection were recmited (age range 23 to 66y).
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Pearson’s Product Moment correlation test. For all tests, p<0.05 was assumed to 
achieve statistical significance.
4.5 RESULTS
NO levels in patients with bronchiectasis
The mean value of exhaled NO levels in bronchiectasis was 6.2 ppb (S.D 2.24) 
compared to 5.0 ppb ( S.D 3.2 ) in CF patients (figure 8). There was no significant 
difference between the two groups. Similarly when patients with bronchiectasis 
were divided into those on inlialed steroids and those that were not, the NO levels 
were not significantly different.
Effect of age on NO levels
There was no coiTelation between age and exhaled NO; r = 0.28, p == 0.2 (healthy 
volunteers) (figure 9)
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Figure 9. Effect of age on exhaled NO levels.
4.6 DISCUSSION
The findings in bronchiectasis were unexpected, since one report had indicated 
that exhaled NO was increased in bronchiectasis (Kharitonov SA, 1995). The 
different methodologies used in measuring exhaled NO may explain the different 
results in the bronchiectasis patients. Kharitonov and colleagues used the peak 
level from a long and slow exhalation as the representative NO value. The peak 
level can be veiy variable and sensitive to even a short period of breath holding 
and, as shown in chapter 2, be influenced by ambient NO levels.
This result suggests that NO in patients with CF is low because of inability to 
detect NO. In both bronchiectasis and CF, gaseous NO could have been prevented 
from diffusing into the aiiivay lumen, either because of physical impedance or 
chemical removal. In the latter, reaction with other reactive species in an inflamed 
environment could effectively remove gaseous NO from the local environment. 
The inflammatory cell influx in both these conditions produces a large amount of 
superoxide and hydrogen peroxide (Greening AP, 1983. Shult PA, 1985. Kinnula 
VL, 1992a&b.). These highly reactive molecules can react with NO to produce 
peroxynitrite and hydroxonium ions (Gaston B, 1994). This would not only 
effectively remove gaseous NO from the environment hut also enhance the 
potential for local tissue damage.
Although the finding o f low NO in both suppurative conditions suggests the above 
theory, this cannot be concluded merely fl'om data collected so far. It does not
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exclude the possibility that NOS II expression is decreased in chronic
The implications of low NO production in the setting of these diseases are 
interesting. I f  production of No is tmly decreased, then the protective anti 
inflammatoiy effects of NO could be lost and inflammation further enhanced. An 
even more important loss would be that of the anti microbial effects of NO. This 
would be particularly pertinent in the setting of chronic bacterial colonisation as
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inflammation. As discussed in chapter 1, it has been shown that NO has an auto 
inhibitory effect on NOS expression ( Rogers NE, 1992. Griscavage JM, 1993. 
Assreuy J, 1993). Also, NOS II protein degradation appears to be enhanced by 
TGFp which is produced in large quantities by activated macrophages ( Ding A, 
1990).
seen in CF and bronchiectasis.
Another relevant effect of NO in CF and bronchiectasis is the modulation of 
chloride channel activity. Kamosinska et al showed that NO can increase chloride 
cuiTents in human epithelial cell line (Kamosinska B, 1997). There is also 
evidence that NO is necessary for ciliary motility (Xue C,1996. Jain B, 1995).
Curiously, patients with Kartegener’s syndrome (ciliary dyskinesia and situs 
inversus) have almost undetectable levels of nasal NO compared to nonnal
subjects (Lundberg JON, 1994). It is unclear from that study whether this is a
.
secondary or primary phenomenon. NOS expression was not examined.
'Ï
J::'
.
Finally, if  the assumption that exhaled NO or NO production is a reflection of 
airways inflammation is incoiTect, then one may not necessarily expect an 
increased level o f NO in suppurative or infective conditions. Indeed, asthma may 
be unique in its high production (or high levels in exhaled breath) o f NO and this 
increase may not be related to anways inflammation.
However, it is important to realise that low exhaled NO levels does not necessarily 
equate to low NO production. It is possible that NO production is nonnal or high 
but simply not detected in the exhaled air. Therefore, before the implications of 
decreased NO production is investigated, finn evidence that NO production is 
indeed decreased should be obtained.
4.7 CONCLUSION
Exhaled NO is not increased in patients with bronchiectasis. This, together with 
similar finding in patients with CF suggests that NO in chronically suppurative 
airways may be impeded from diffusing into the airway lumen and thus detection 
of gaseous NO is limited. It is also possible that NOS II is downregulated in 
chronic inflammation.
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CH A PTER S  
EVIDENCE FOR M OLECULAR PRESENCE OF NOS II IN CYSTIC  
FIBROSIS EPITHELIAL CELL LINES AND PRIMARY NASAL  
EPITHELIAL CULTURES
5.1 INTRODUCTION
In order to examine if  lack o f increase in exhaled NO levels in patients with 
cystic fibrosis may be due to the lack o f production, I investigated if one o f the 
genes responsible for its production (NOS II or iNOS) is expressed in CF cells. 
Type II NOS was chosen because it is the enzyme responsible for the largest 
amount o f NO generation. Also, evidence at the time of study design suggested 
that NOS II expression was increased in airway inflammation (see chapter 1.6.3 ). 
In the lungs, type II NOS has been localised in neutrophils, eosinophils, alveolar 
macrophages and epithelial cells (Gaston B, 1994). Its expression upon 
stimulation by proinflammatory agents (Robbins RA, 1994) indicates its 
importance in inflammation while the loss of defence against intracellular 
pathogens in an NOS II knockout mouse implicates its role in host defence (Wei 
XQ, 1995). Bronchoalveolar lavage of CF lungs has demonstrated raised IL8 
levels and a predominantly neutrophilic inflammatory cell influx (Dean TP, 1993. 
Dosanjh AK, 1998. Bonfield TL, 1995). However, as seen in chapter 3, exhaled 
NO levels are low in CF patients, even during infective pulmonary exacerbations. 
Similarly nasal NO levels which are in the order of 500 ppb in nonnal subjects 
have been found to be significantly lower in CF patients (10 ppb), raising the
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question o f NOS expression in CF epithelial cells. Therefore, one possible 
explanation for the lack of increase of exhaled NO levels in CF might be the 
inability to upregulate NOS II in CF epithelium.
5.2 HYPOTHESIS
The lack of increase in exhaled NO levels in the inflammatory setting of CF 
airways may be secondary to loss of NOS II expression in epithelial cells.
5.3 AIMS OF STUDY
The study investigates the basal and stimulated expression o f NOS II in primary 
human nasal epithelial cells, since these may be representative of cells in the 
lower airways. Expression of NOS II in the airway epithelial cell line (SCFTE) 
(Gruenert DC, 1995) expressing the most common CFTR mutation, 5F508 was 
also studied to complement the primary culture experiments.
Experiments were perfoimed to address the following questions:
(a) Is NOS II expression in CF epithelial cell lines and CF nasal epithelial cells 
altered compared to nonnal controls?
(b) Is this expression increased in vitro on stimulation with proinflammatory 
cytokines and the bacterial product, lipopolysaccharide (EPS)?
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5.4 M ATERIALS AND METHODS
5.4.1 CELL CULTURE  
Primary nasal epithelial cell culture
Nasal epithelial cells were haiwested from the inferior turbinate of subjects using a 
bronchoscopy cytology brush (BC-5, Olympus Keymed, Essex, England). The 
brush was advanced and retrieved quickly along the floor o f the nose. No local 
anaesthetic was used. Both nostrils were brushed three times.
Brushings were obtained from 3 CF patients (all ÔF508 homozygotes), 3 normal 
subjects and 3 asthmatics. Astlnnatics acted as positive controls since they are 
known to have increased NOS II gene expression and thus acted as positive 
controls. All subjects were non smokers and did not have active allergic rhinitis or 
upper respiratory tract infection during, and for 6 weeks before, the procedure. 
None o f the patients were on inlialed steroids at the time of sampling.
After harvesting, cells were re-suspended within 10 minutes in Ham’s F I2 culture 
media (GIBCO), supplemented with 2% Ultroser G (IBF Biotechnics), 1% 
Glutamine, 1% non essential amino acid, 2% penicillin/streptomycin, 0.1% 
gentamicin and 1% Amphotericin B (all from Life Technologies) and incubated 
in 5% COj in air at 37°C. For each subject, the total cells were divided into 4
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wells. Three wells were used for stimulation studies, while the fourth acted as a 
control where no stimulants (cytokines and LPS) were added.
Cell viability was assessed by ciliary motility and only wells with at least 90% of 
cells exhibiting ciliary motion were used. Cells were grown in 96 well plates and 
all samples contained at least 90% of ciliated epithelial cells (figure 10 and 11). 
They were incubated for half an hour before stimulation with 200 \xl of medium 
containing 10 ng/ml each of ILIp, TNFa and IFNy, and 10 pg/ml o f LPS for 5 
hours.
RNA extraction was perfonned at the end of stimulation (chapter 5.4.2). 
Epithelial cell lines
A human CF tracheal epithelial cell line expressing the 5F508 mutation, ZCFTE, 
and for control a normal human bronchial epithelial cell line, 16 HBE (both gifts 
from Professor D Gruenert, UCSF, California) were propagated in MEM 
medium (GIBCO BRL) with 10% foetal calf serum, supplemented with 
penicillin/streptomycin, 0,5 mM L-arginine and glutamine in a 5-6% COg 
incubator at 37°C. Cells were grown to 90% confluence on fibronectin/collagen 
coated 6 well plates prior to stimulation. As described with the primary cells, 
these cells were divided into stimulated (with 15 ng each of IL ip , TNFa and 
IFNy, and 15 pg of LPS in 1.5 ml of culture medium) and unstimulated samples 
and incubated for 8 and 24 hours before RNA extraction.
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5.4.2 MOLECULAR BIOLOGY
RNA extraction. Both primary cultures and cell lines were prepared in the same 
manner. Cell lines but not primary cells were washed with ice cold phosphate 
buffered saline (PBS). Total RNA was extracted as follows. Culture media was 
first removed fi'om cell culture wells. 1 ml RNAzol B (Boehringer Mannheim) 
was added to each well to lyse cells. Lysed cells are then reacted with 100 pi 
chloroform, spun down and 450 pi of top layer removed. RNA is precipitated 
from this layer by addition of 4 pi of glycogen (10 mg/ml) and 450 pi 
Isopropanolol. This was allowed to react for 15 minutes and then RNA pelleted by 
centrifuging for 15 minutes. This pellet was washed with 75% ethanol and final 
pellet resuspended in sterile water.
Reverse transcription. 2 pi of prepared RNA suspended in DEPC treated water 
was denatured at 65°C for 15 minutes. cDNA is synthesised from RNA according 
to protocol from Boehringer Mannheim [ 1st strand cDNA synthesis kit for RT- 
PCR (AMV)] (Appendix) in a 20 pi reaction containing 2 pi of lOx reaction 
buffer, 5 mM of MgClj, 1 mM of deoxynucleotide mix (dNTPs), 0.4 pi of gelatin 
(at 0.01 mg/ml), 3.2 pg of p(dN)g primer, 50 units of RNAse inliibitor and 0.8 pi 
(20 units) AMV-reverse transcriptase at 42°C for 60 minutes. Negative control 
tubes containing no RNA were also included.
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PCR. A  semi quantitative PCR was employed, according to methods and primers 
described by Watkins DN et al (Watkins DN, 1997). The following 
oligonucleotide primers for reverse transcription PCR were used:
NOS II (+) : 5’ ACGTGCGTTACTCCACCAAC-3'
NOS II (-): 5’ TCGCAAA GAGGATGGTGACT-3’
This was obtained from Genosys, UK. This produced a 945 bp PCR product.
Primers for p actin, a housekeeping gene was also used in a duplex reaction, using 
the following oligonucleotide primers:
P actin (+): 5’ CGTGACATTAAGGAGAAGCTGTGC-3’ 
p actin (-): 5’ CTCAG GAGGAGCAATGA TC TTGAT-3’
A 25 pi PCR reaction mixture containing 2.5 pi Perkin Elmer lOx buffer, 1.5 pi 
o f 25 mM MgCl%, 50 ng of specific primers, 1 unit AmpHtaq DNA polymerase 
and 0.625 pi of 10 mM dNTPs is prepared with 10 pi of cDNA. Dénaturation, 
annealing and extension temperatures for PCR were 94°C, 55°C and 72°C for 36 
cycles.
Products were electrophoresed on a 2% agarose gel. Each sample was compared 
to a negative control which did not contain reverse transcriptase and samples 
containing DEPC treated water and no RNA acted as further negative controls. 1
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pg samples of plasmid DNA (gift fi'om Dr. Watkins, Queen Elizabeth II Medical 
Centre, Australia) acted as positive controls.
Southern blotting, RT-PCR products were detected by Southern blotting using
end labeled oligonucleotides specific for the NOS II and p actin genes. Specific
Jf
intron spanning 20 mer primers were designed horn published cDNA sequences 
obtained from Geller DA et al (Geller DA, 1993a). PCR products were transferred 
to a Hybond N nylon membrane by capillary blotting in lOx saline sodium 
citrate (SSC). Membranes were hybridised at 58°C in 5 X SSC and 0.5% SDS and 
lOpg heat denatured salmon sperm DNA and 50 ng of heat denatured probe. High 
stringency wash in 4 x SSC was performed twice before membranes were opposed 
to a phosphoimager for 24 hours. The images from the phosphor image were 
processed using the ImageQuant™ programme.
5.5 DATA ANALYSIS
For the cell line experiment, gene expression of NOS II is represented numerically 
as a percentage o f p actin expression. This is perfoimed on the ImageQuant ™ 
programme.
For primary cell suspension experiments, numerical expression was not calculated 
because it was not possible to ensure that p actin expression was derived purely 
from epithelial cells. Thus, the primary culture experiments were regarded as 
supportive evidence for the cell line experiments.
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5.6 RESULTS  
NOS II expression in primary epithelial cells from normal, CF and asthma 
patients
In unstimulated samples, NOS II mRNA was only detected in asthmatic samples 
(figure 12). However, NOS II mRNA expression was seen in all stimulated 
samples (at least 2 o f thi'ee wells for each subject). The housekeeping gene, p- 
actin mRNA was detected in all samples. All controls (minus reverse 
transcriptase, water control and minus RNA control) showed no signal, indicating 
no false positive signals.
NOS II expression in normal and CF epithelial cell lines
Both ECFTE and 16 HBE cell lines showed expression of NOS II at baseline with 
increased expression after 8 and 24 hours stimulation [% NOS II/p actin = 12.7 v
32.2 V 36.7 (16 HBE) and 20.3 v 23.0 v 50.9 (ECFTE) respectively], (Figures 
13a&b and 14)
5.7 DISCUSSION
These experiments demonstrated that NOS II expression in CF nasal epithelia, in 
contrast to asthmatics, is not increased prior to further stimulation with 
proinflammatory cytokines. Both cell line and primaiy culture experiments show
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Figure 13a . Phosphorimages o f  Southern blots showing expression o f iNOS in 
normal cell line ( 16 HBE) from one experiment.
MW=molecular weight marker. 8a-c and 24a-c= Unstimulated wells at 8 and 24 
hours respectively. 8as-cs and 24 as-cs =Wells stimulated with 10 ng/ml o f  ILip,
IFNy, TN Fa and 10 pg/ml o f  EPS for 8 and 24 hours respectively. +=with reverse 
transcriptase; -=no reverse transcriptase control. Controls ; (1) -RNA= PCR mix 
without RNA. (2) H^O = PCR mix with sterile water without cDNA.
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transcriptase; -=no reverse transcriptase control. Controls : (1) -RNA= PCR mix 
without RNA. (2) H^ O = PCR mix with sterile water without cDNA.
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that NOS II expression and response to pro-inflammatory cytokines are similar 
to normal cells.
From these results it can be concluded that:
1. the presence of CFTR gene mutation do not affect the expression of NOS II in 
response to inflammatory stimuli. Therefore, low levels of exhaled NO in CF 
are not secondaiy to abnormal expression of the NOS II gene to inflammatory 
stimuli.
2. NOS II expression is increased in asthmatics but not in CF epithelia compared 
to normal subjects.
The aim o f the study was to examine if lack of NOS II expression accounted for 
the low levels o f exhaled NO in CF patients. The definitive study would be to 
obtain biopsies from the lower airways of patients with CF, However, we did not 
have ethical permission for this. I examined, instead, the nasal epithelium taking it 
as a representative of the lower ah*ways. This presented a few limitations. Firstly, 
bronchial sepsis that occurs in the lower aii*ways is not present to the same degree 
in the upper ahivays. So, definitive conclusions about the expression of NOS II in 
response to suppurative enviromnent camiot be derived. Secondly, the precise 
nature of the primary cell cultures were a little uncertain. Although visual 
observation showed almost 90% of cells to be ciliated epithelial cells, I could not 
exclude the possibility of some inflammatory cells in the culture. The only way of 
excluding inflammatory or other cells would have been to allow the epithelial 
cells to adhere and grow to confluence. However, although adherence of the cells
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would have allowed washing off of ‘contaminant’ cells, it would have created the 
possibility of dedifferentiation of the cells and natural loss of NOS II expression 
as demonstrated by Guo et al (Guo FH, 1995).
Therefore, horn this study it could only be concluded that NOS II expression in 
the lower airways of CF, like that in the upper respiratoiy tract (nose) is likely to 
increase in response to inflammatory stimuli in bronchial sepsis.
That aside, a few interesting suggestions arise from these results. In view of 
increased background inflammation compared to noimal subjects, the expectation 
is for CF epithelial cells to have increased constitutive expression o f NOS II, as in 
asthmatic epithelium. Despite these cells being nasal rather than lower aiiivay 
cells exposed to bronchial sepsis, previous experiments in our laboratory had 
shown that nasal biopsies obtained from CF patients demonstrated excess 
inflammatory cell infiltrate (Poiteous DJ, 1997). Hence, it seems that at the 
cellular level, there appear to be persistent inflammatory stimuli in the nasal 
epithelium, but these do not appear to result in upregulation o f NOS I I . It may be 
that asthmatic epithelia are unique in the upregulation of the NOS II gene in 
vivo. This may be secondaiy to a genetic predisposition to epithelial upregulation 
o f NOS II.
At the time o f conclusion o f these experiments, Polak’s group published a study in 
which the NOS II expression in CF cell lines and bronchial explants from end 
stage CF patients undergoing heart lung transplant were examined (Meng Q-H,
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1998). They found decreased expression o f NOS II in these explants and no 
expression in CF epithelial cell line even after stimulation with proinflammatory 
cytokines and LPS. They speculated from their findings that the loss of NOS II 
expression may be secondary to the presence of CFTR mutation. My findings 
would suggest otherwise, since NOS II is cleaiiy expressed in the CF cell lines 
used and it appears more likely that in the presence of persistent chronic 
inflammation, NOS II expression is downi'egulated and that this effect is unlikely 
to be unique to CF.
5.8 CONCLUSION
CF epithelial cells, in vitro, are able to express NOS II nonnally in response to 
inflammatory stimuli. The studies, however, do not exclude the possibility that 
NOS II expression may be down regulated by chronic inflammatory stimulation.
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CHAPTER 6 
DEVELOPM ENT OF BREATH CONDENSATE M ETHODOLOGY
6.1 INTRODUCTION
As discussed in chapter 4.6, one way of exploring NO production in the lower 
airways is to examine a surrogate marker of this production. This can take the 
form of an end metabolite like nitrite. Four methods have been developed for 
sampling of the lower airways for cellular and biochemical activity. They are 
bronchoalveolar lavage (BAL), induced sputum production, exhaled air and 
condensed breath. BAL is the oldest of the methods but is also the most invasive 
and has led to a few asthma deaths (O’Byrne PM, 1994). Breath condensate and 
exhaled air methods are the least invasive, and arguably sample the whole of the 
lungs rather than a localised area and provide information on 
physiological/cellular activity at the time of sampling. They are relative new and 
the least investigated o f the four methods.
The concept o f  using breath condensate as a medium to measure suiTogate
I:markers o f  airways pathophysiological activity has been suggested since the early
:Y:.
f .
1980’s. Then, volatile hydrocarbons were detected in exhaled breath by mass 
spectrometry and spontaneous chemiluminescence was observed in condensed 
breath (Barkley J, 1980). More than 200 different volatile components have since 
been identified in the exhaled air (Manolis A. 1983). The method of detecting
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substances o f interest in the breath originated horn the idea that volatile 
hydrophilic substances can be concentrated as condensate after passing the warm 
(36.9°C) exhaled breath tlirough a cold trap. Hydrogen peroxide, a volatile oxygen 
metabolite can enter the gaseous phase at physiological temperatures (Williams 
MD, 1982) and has been shown to be detectable in breath condensates. The levels 
o f non volatile but water soluble compounds can also be measured in micro­
aerosols produced in condensed exhaled air (Scheideler L, 1993). The use of 
breath condensate as a research tool is not widespread. This is partly due to the 
complicated and prolonged collection period to acquire enough fluid for analysis. 
However, the advantages o f this method over induced sputum and 
bronchoalveolar lavage make it a very attractive option to pursue.
I wanted to develop a collection method that would incorporate the following 
features:
1) The method should collect enough condensate in a short period of time. This 
is necessary to ensure that condensate is present in the cold trap for a 
minimum amount o f time before analysis or storage so as to prevent 
degradation of molecules of interest.
2) The method should be acceptable to patients particularly in CF where the 
expiration phase could be decreased due to reduction in total lung capacity.
3) There should be no salivary contamination.
4) Minimal or no contribution of air from the nasal passages to the exhaled air.
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6.2 METHODOLOGY AND EQUIPMENT
6.2.1 COLLECTION OF BREATH CONDENSATE
METHODS
acceptable .
Approximately one ml of breath condensate could be obtained within 6  minutes 
using this method. In order to prevent saliva contamination, the collection tubing
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Teflon perfiuoralkoxy was used for the collecting tube. This is an inert material 
,which ensuied that no reaction occured between the molecules o f interest and 
collecting tubes. The tubing had a 0.5 cm diameter and was initially coiled in an S 
shape to collect breath condensate at the most dependent area (Figure 15a). This 
suffered from salivary contamination and poor volume collection. The setup was 
thus modified to incorporate a system that allowed increased surface area in order 
that more condensate can be collected over a shorter period of time. This was 
achieved by coiling the tube and using a container with a confined space to 
maintain the coils. Different number of coils were used but the increase in surface 
area afforded by the increase in the coils was limited by the resistance to 
exhalation that this created (Figure 15b). Two and a half coils were found to 
provide the best compromise. Patient acceptability in tenns of ability to exhale 
into the tube over 5-6 minutes duration was tested on three CF subjects with
different lung function (FEVl 37% to 85% of predicted). All found the method
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was placed about 5 inches higher than the subjects mouth. The subject was also 
instructed to swallow his or her saliva before exhalation and to do this at intervals 
throughout the procedure.
6.2.2 SALIVA CONTAM INATION
M ETHODS
To test that this method excluded salivary contamination, breath condensate 
samples were collected in 15 CF subjects over 6  minutes and each tested for 
salivary amylase using a reflectrometric diy slide method with a Vitros analyser 
(Ortho Clinical Diagnostics, Strasbourg). Two samples were ‘spiked’ with 0.5 ml 
o f saliva to ensure that this method of detection worked.
RESULTS
I found no salivary amylase in any of the samples collected. In contrast the spiked 
samples showed levels in excess of 2 0 , 0 0 0  lU.
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6.2.3. NASAL AIR CONTAMINATION
M ETHODS
Two subjects were asked to exhale into the Teflon tube in the standard fashion 
while their noses were being flushed with 100% helium (BOC, Kent) delivered by 
nasal canulae. (The helium flushing started after inspiration). Expirate emerging 
from the collecting tube was continuously sampled for helium using a helium 
analyser (an integral part of a standard body plethysmograph). This was 
performed during and for 15 seconds after the end of exhalation. In order to 
establish that this system could detect helium in the expirate, the subjects inhaled 
to TLC while the nose was flushed with 100% helium and then exhaled into the 
collecting system where expirate was tested for helium as above.
RESULTS
Both subjects who inhaled to TLC while their noses were being flushed with 
1 0 0 % helium had detectable helium in their expired air within the first 15 seconds 
( 2.8% and 1.5% respectively). However, exhaled air tested when helium was 
delivered to the nose after the start o f exhalation showed no helium in the 
expirate. These data indicate that the method of exhaling against the resistance of 
the tubing is sufficient to exclude contamination of the expirate by nasal air, 
presumably by elevating the soft palate and sealing off the posterior nasopharynx.
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6.3 FINAL METHOD
In the final method, breath condensate was collected by asking the subject to 
inspire repeatedly to total lung capacity (TLC) and exhale tlirough 1.5 m Teflon 
perfiuoralkoxy (PFA) tubing with 0.5 cm internal diameter, immersed in ice 
(figure 15b). Subjects were asked to keep their mouth dry by swallowing their 
saliva throughout the procedure. This method yielded one ml o f breath condensate 
within 6 - 8  minutes.
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—7.1 INTRODUCTION
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CHAPTER?
%
DEVELOPMENT OF NITRITE ASSAY FOR BREATH CONDENSATE
In an oxygenated aqueous environment, rapid interconversion among NO species 
.may occur as described in chapter 1.2. In the air-fluid interface o f the aiiways, NO 
generation may be indicated by the formation of stable end products of NO 
metabolism, nitrite (NOj’ ) and nitrate (NOg ).
At this point in time of the MD project, no one had investigated the possibility of
detecting nitrite in exhaled breath condensate. In theory, nitrite, being water
soluble would be present in the lining fluid of airways. At 37°C, expired breath
contains volatile substances and water vapour of which some would have
originated fi'om the inspired breath and others derived from the airway lining
fluid. It would also contain micro aerosol which may have been generated by the 
.expiration against a mild resistance. Scheideler et al had shown that IL lp , sIL2R
-,
and TNFa could be detected in condensed breath (Scheideler L, 1993). Since
these molecules were non soluble, it meant that their detection was made possible !
by condensed micro aerosol generated from the airway lining fluid. It also allowed
me to speculate that there was a high probability that a water soluble molecule like
nitrite would be detectable.
Nitrite rather than nitrate was selected for the study for three reasons. Firstly it is 
the main end product o f NO metabolism and nitrate is ftequently reduced to nitrite 
in biological systems (Marietta MA, 1988). Secondly, the use of one simple and 
reliable method of measurement (Griess reaction) decreased the need for increased 
condensate collection. Thirdly, in a previous (umrelated) study examining NO 
production in cultured chondrocytes I had already demonstrated that nitrate and 
nitrite generation correlated strongly with each other (r=0.99) (Ralston S, 1995).
7.2 HYPOTHESIS
Nitrite levels can be measured in condensed expired breath and this may be a 
surrogate marker of NO production in the lower airways of patients with cystic 
fibrosis.
7.3 METHODS
The first task was to evaluate if  nitrite could be detected in the breath condensate 
and then to validate the reproducibility and sensitivity of the assay.
Nitrite assay- Griess reaction
I employed a well established method commonly used for measuring nitrite levels 
in cell culture studies - the Griess reaction (Green LC, 1982). This is a
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colorimetric method where the diazotization o f the Griess reagent (1% 
sulfanilamide dihydrochloride and 2.5% H3 PO 4 ) by nitrite causes a colorimetric 
change. The intensity o f this colour change correlates to the concentration of 
nitrite and is detected on a spectrophotometrically. The Griess reagent is prepared 
fresh on the day of use by adding reagent A and B at 1:1 vohvol. (Reagent A: 2% 
sulfanilamide in orthophosphoric acid. Reagent B: 0.2% N-1- naphthyl 
ethylenedianiine dihydrochloride (NED) in water). A standard curve is derived on 
the day o f use from a stock of 100 mM of sodium nitrite (0.069 g in 10 ml 
distilled water) to give a concentration of 0- 10 pM.
Ability to detect nitrite in breath condensate
This protocol was applied to breath condensate collected from four normal 
subjects and two asthmatics and two CF patients.
Reproducibility
Intrasubject reproducibility on different days (3 - 8  days) was assessed in 7 
normal subjects. Bartlett’s test was first applied to test for heterogeneity of 
variance between individuals and then ANOVA was applied to give a pooled 
standard deviation and 95% confidence inteival.
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7.4 RESULTS 
Nitrite assay
The standard curve showed that the assay was able to detect nitrite levels as low 
as 0.5 pM and a standard curve from 0 to 10 pM consistently showed a linear 
relationship with the spectrophotometric reading (r = 0.99) (figure 16). Nitrite 
was detected in all samples collected from all subjects and was noted to be 
considerably higher in astlimatics (table 1 0 ).
Final methodology
Triplicates o f 100 pi of breath condensate were reacted with 25 pi of Griess 
reagent (0.1% naphthylethylene diamine dihydrochloride, 1% sulfanilamide, 3% 
H3PO4) and measured at absorbance of 570 nm with a microplate reader (MR 710, 
Dynatech). A fi-esh standard cuiwe is prepared for each batch of experiments using 
the same reagents as for the samples. Breath condensate collections were 
perfoimed as described in chapter 6 .2 .
Intrasubject variation.
Nitrite levels in individual subjects are shown in table 11.
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Figure 16. Typical standard curve for Imown nitrite concentrations derived using 
Griess reaction.
Breath condensate nitrite (jrM)
Normal subject 1 0.60 0.64
Normal subject 2 1 . 2 0 1.46
Normal subject 3 1 . 1 0 1 . 0
Nonnal subject 4 0.52 0.54
CF 1 4.30 4.04
C F2 2 . 1 0 2 . 1 0
Asthma 1 8 . 1 0 8.42
Astlmia 2 4.40 4.00
Table 10. Preliminary values o f nitrite in asthmatics, CF and normals from one
collection on same day.
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Breath condensate nitrite levels (pM)
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8
Subject 1 1.0 0.0 0.24 0.06
Subject 2 1.0 1.46
Subject 3 1.1 0.28 1.2
Subject 4 0.0 0.52 0.76
Subject 5 1.1 0.6 1.72 0.67 0.32 0.56 0.98
Subject 6 0.28 1.29 0.32
Subject 7 0.88 0.32
Table 11. Values o f breath condensate nitrite (pM) in normal subjects on 
different days.
s
I
%i■
t
I
,6"
118
Bartlett’s test showed no significant difference between the individuals tested 
(p=0.91), thus ANOVA to the whole group could be applied. This gave a pooled 
S.D. o f 0.5 pM, and a 95% confidence interval for any measure of ±1.12 pM.
'S
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CHAPTER 8 
NITRITE LEVELS IN EXPIRED BREATH OF CYSTIC FIBROSIS 
PATIENTS
8.1 INTRODUCTION
Contrary to expectations, exhaled NO levels in cystic fibrosis have been found to 
be low, even during infective pulmonaiy exacerbations. As discussed, one 
explanation is that NO in the gaseous phase may be “trapped” by the viscous 
secretions in suppurative lung conditions and effectively be removed by its 
reaction with reactive oxygen species or with water and oxygen. Having 
demonstrated that nitrite is measurable in breath condensate, I proceeded to 
examine the levels in CF patients compared to normal subjects. The relationships 
o f breath condensate nitrite with circulating plasma leucocytes, exhaled NO, 
conventional lung function measurements and the use of inhaled steroids were 
also analysed.
8 2  h y p o t h e s i s
It is hypothesised that in CF airnays, excess gaseous NO from inflamed airways is 
converted to nitrite and nitrate close to the site of production before it is able to 
move into the airway lumen and be detected as gaseous NO. Thus nitrite levels in 
breath condensate o f CF patients would be elevated compared to nonnal subjects.
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8.3 STUDY DESIGN  
Subjects and patients
Twenty one clinically stable CF patients with defined genotypes were recruited. 
Lung functions were variable, with FEV, as percentage of predicted ranging fiom 
20 % to 95 % ; mean (± S.D.), 57 (24) %. The mean age for the patients was 
26.0 (9.3) years. There were 13 males and 8  females. Twelve healthy normal 
volunteers acted as controls, with mean age 31.4 (4.9) years ( 6  males, 6  females). 
All subjects were non smokers and had no intercurrent respiratory tract infection, 
active allergic rhinitis or concomitant aiiways diseases.
All CF patients had spirometry and reversibility to salbutamol. Patients with 
reversible airways obstruction (increase in FEV, of greater than 175 ml after 2.5
mg nebulised Salbutamol) or clinical evidence of asthma were excluded. Within 
the CF group, 9 were on inlialed steroids, ranging from 200 meg to 1500 meg 
beclomethasone dipropionate per day which was started by their usual physician 
as anti-inflammatory treatment.
Breath condensate nitrite and exhaled NO of all patients were measured on two 
separate days. On all occasions, the patients were clinically stable and lung 
function (FEVJ was unchanged (< 175 ml). Fourteen subjects consented to 
venepunctme for measurement of circulating white cell count and differential
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white cell count (neutrophils, eosinophils, monocytes and lymphocytes). This was 
performed on the day o f breath collection.
Measurement of exhaled NO and breath condensate were as described in chapters
2.3 and 6.2 respectively.
8.4 STATISTICAL ANALYSES
Comparisons between the two groups were made using the Maim Whitney Rank 
Sum Test. Correlations between nitrite levels and exhaled NO and between nitrite 
and lung function (FEV,) were determined using the Speaiman Rank Sum Test.
8.5 RESULTS 
Nitrite and exhaled NO levels in CF compared to controls
Nitrite levels were significantly higher in CF patients compared to normal subjects 
(median 1.93 pM compared to 0.33 pM, p < 0.001) (figure 17 and table 12).
In contrast, exhaled NO values were not significantly different compared to the 
normal range [median of 3.8 ( 95% confidence interval 3.4-5.2) ppb vs 4.4 (2.9 - 
6.3) ppb].
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Figure 17. Nitrite levels in breath condensate of patients with cystic fibrosis compared 
to normal subjects.
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Correlation between nitrite levels and plasma leukocyte levels, lung function 
and inhaled steroid usage
There was a positive conelation between nitrite levels and circulating leucocytes 
and neutrophils (r=0.6, p=0.04 and r=0.6, p=0.03 respectively by Spearman Rank 
Order Correlation) (figure 18). In contrast, there was no correlation between 
exhaled NO and circulating plasma leukocyte count. Nitrite levels were not 
significantly different between the patients taking and those not taking inhaled 
steroids (table 1 2 ).
There was no correlation between breath condensate nitrite and exhaled NO or any 
between breath condensate nitrite and lung function (figures 19 and 2 0 ).
8.6 DISCUSSION
This study has demonstrated that, compared to normal subjects, nitrite levels in 
breath condensate were higher in CF patients but confinned again that this was 
not the case with exhaled NO. It also showed that there is no relationship between 
exhaled NO and nitrite levels.
This suggests that exhaled NO may not reflect total NO production in the airways, 
particularly if  the airways are chronically suppurative. It is likely that NO, as it is 
being produced, is converted to nitrite and possibly nitrate (although this was not 
measured here) before it has the chance to diffuse into the lumen as gaseous NO.
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Figure 18. Correlation between breath condensate nitrite levels inpatients with cystic 
fibrosis and their peripheral neutrophil levels.
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Figure 19. Relationship between breath condensate nitrite levels and exhaled NO levels 
in patients with CF.
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Figure 20. Relationship between breath condensate nitrite levels and lung function 
in patients with CF.
Excess secretions and mucus in CF aii^ways may inhibit diffusion of gaseous NO 
into the airways lumen and encourage interaction with the epithelial lining fluid, 
forming nitrite and nitrate. Other factors may contribute to its removal fi*om 
detection as gaseous NO, for example reaction with other reactive oxygen species 
such as superoxide to foim peroxynitrite. It is possible that elevated levels of 
gaseous NO reflect very high levels o f NO production which is surplus to that 
which has metabolised at the site of production.
Breath condensate nitrite also appeared to coiTelate with peripheral blood total 
leukocyte counts. It is possible therefore, that nitrite levels in the airways may 
reflect the burden of inflammation in the airways. It is not suiprising to find no 
correlation between nitrite levels with lung function in spite of its relationship 
with leukocyte coimt. This is because FEV, in CF patient can be regarded as a 
Tate’ event in the chain of disease processes. It reflects a combination of 
irreversible end stage airway damage and fibrosis, degree of bacterial colonisation 
and mucus plugging and may not bear any relationship with ongoing 
inflammation at the time of sampling. This is particularly pertinent in clinically 
stable patients as in this study. The finding that inlialed steroids did not affect 
nitrite levels was more unexpected. It is possible that large parts of the airways in 
suppurative airways disease like CF are inaccessible to inhaled medication. Lack 
of compliance with medication in this group of patients could also be a 
contributory factor to this unexpected result.
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Breath condensate nitrite, like exhaled gaseous NO gives no information as to the 
cellular source of NO production. Polak’s group (Meng Q~H, 1998) found that 
there was significantly decreased or absent epithelial NOS II expression in 
bronchial explants from end stage CF patients. Our finding is not inconsistent with 
this, since nitrite levels that we measured may have reflected NO produced by 
inflammatory cells rather than epithelial cells. This is supported by the 
relationship with circulating plasma neutrophils and also Polak’s finding that NOS 
II appeared to be nonnally expressed in neutrophils found in CF airways. 
Grasseman and colleagues (Grasseman H, 1997. Grasseman H, 1998) have also 
demonstrated high levels of a related NO metabolite, nitrate, in bronchoalveolar 
lavage fluid of children with pneumonia and CF, supporting my hypothesis that in 
inflamed aiiways, a significant proportion of NO fiom the lower airways may 
have been oxidised to nitrite and nitrate.
8.7 CONCLUSION
Breath condensate nitrite levels are elevated in clinically stable CF patients 
compared to noimal controls and is possibly a more sensitive marker of airways 
NO production compared to exhaled NO. It may be more useful as a marker of 
airways inflammation compared to exhaled gaseous NO in suppurative airways 
disease. The findings from the study also suggest that NO generation is high in 
cystic fibrosis aiiways in spite of low exhaled NO levels, and that this is likely to 
be mainly attributable to production by inflammatory cells.
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CHAPTER 9 
DEVELOPM ENT OF HYDROGEN PEROXIDE ASSAY FOR BREATH  
CONDENSATE
9.1 BACKGROUND
Oxidant induced cellular damage plays a significant role in the pathogenesis of 
many diseases (Kiimula VL, 1995). The impact of free radicals may be especially 
important in the lung because o f its great surface area and exposure to higher 
concentrations o f oxygen than other tissues. The fi*ee radical burden occurs as a 
byproduct of cellular oxidative metabolism and, in the lung, is further increased 
by inhaled toxic particles and gases. There is evidence that oxidants play a central 
role in the pathogenesis of many pulmonaiy diseases, such as fibrosing alveolitis, 
emphysema, asthma and ARDS (Barnes PJ, 1990. Crystal RG, 1991. Heffiier JE, 
1989. Kamp DW, 1992. Sibille Y, 1990). The mechanisms contributing to free 
radical related tissue injury include reactive oxygen species generation by both 
normal lung cells and by inflammatory cells.
The primary reactive oxygen metabolites formed in vivo are superoxide and 
hydrogen peroxide. The latter is also generated through non-enzymatic or 
enzymatic dismutation of superoxide. These radicals, although toxic themselves, 
generate an even more reactive and harmful radical - the hydroxyl radical 
(Halliwell B, 1990). Given the potential deleterious effects of these molecules, the
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Measurement of H 2 O 2  therefore may be seen to reflect the oxidant burden in 
biological systems. In conditions like cystic fibrosis, it may be a reflection of the 
inflammatory cell activity or a measure of phagocyte response to stimulation. The
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lungs (and other cells) have efficient antioxidant defence mechanisms and various 
lung cell types differ in their resistance against oxidants, partly due to differences 
in these antioxidant defence mechanisms.
Hydrogen peroxide is primarily produced by mechanisms that produce superoxide 
in the cytoplasm, mitochondria or endoplasmic reticulum (Kinnula VL, 1995).
This is generated tlxrough enzymatic or non enzymatic dismutation and occurs 
physiologically as a byproduct o f mitochondrial respiration or via cytoplasmic
'
reactions catalysed by enzymes like xanthine oxidase. Such H 2 O2  production is 
contained within the cell by rapid scavenging locally. However, H 2 O 2  is more 
stable than superoxide and diffuses easily tlirough the plasma membrane.
Therefore, in circumstances when intracellular H 2 O2  generation exceeds the 
capacity o f the antioxidant scavenging systems of the cell (catalase and 
glutathione), it diffuses extracellularly (Kinnula VL, 1992c). Extracellular release 
also occurs from activated inflammatoiy cells and cells like alveolar epithelial and 
vascular endothelial cells, partly fr om superoxide generation at the cell membrane
:
(Dupuy C, 1991. Kinnula VL, 1992a). Production by this method is usually much 
greater and is catalysed by membrane associated NADPH oxidase. This forms the 
respiratory burst in these cells which are stimulated by various proinflammatoiy
agents.
.
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finding that nitrite, but not gaseous NO, levels are increased in exhaled air of CF 
patients suggests that NO, being a highly reactive molecule, may have reacted 
close to its site of production (e.g. to an end metabolite like nitrite) and is 
prevented from being detected in the exhaled air. I was interested in investigating 
the levels o f H 2 O2  in the exhaled air for two reasons:
1 . If  the hypothesis that NO production in CF is high but simply not detected 
because it has reacted close to its site of production or because its diffusion into 
the gaseous phase is impeded by secretions is conect then H 2 O 2 , being a 
highly reactive molecule, would suffer the same fate.
2. If, the above hypothesis is not tme and the levels of H^Og in breath condensate 
are high then this may be a useful method for monitoring response of airways 
inflammation to novel treatment in CF (e.g. gene therapy, chapter 1.8.3.2).
The first task was to validate a method for measuring H 2 O 2  produced in the 
airways.
9.2 METHODS
Several methods have been used for the deteimination of H 2 O2  (Root RK, 1975.
Ruch W, 1983 Roberts IM, 1991. Cathcart R, 1983. Giulivi C 1994. Pick E, 
1980). Almost all utilised the principle o f fluorometiy where hydrogen peroxidase 
catalyses the oxidation of a compound (‘substrate’) by hydrogen peroxide to form 
a fluorogenic molecule. Most of the substrates are phenolic compounds which act
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coniplexed with H 2 O2 , has also been used as an indirect assay. However, it is not 
suitable for phagocytic studies as these cells only have low levels of catalase (Gee 
JBL, 1970). The most commonly used assay is probably one based on the
dependent oxidation o f scopoletin (Root RK, 1975). It has high sensitivity but 
unfortunately suffers from a few disadvantages. A non-linear loss of fluorescence
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as hydrogen donors. The choice of substrate may be determined by the system to 
be tested; e.g. in cell culture experiments, p-hydroxyphenyl acetic acid may be %
cytotoxic in certain concentrations and therefore other substrates like homo vanillic
'7'
acid may be preferable.
Other methods use CO2  liberation from catalase dependent oxidation of 
radiolabelled fonnate (Iyer GYN, 1961). The main disadvantage o f this method is 
the need of incubation vessels suitable for the trapping of gaseous CO 2 . Inhibition 
of cellular catalase by aminotriazole, catalase being susceptible to this only when
quenching o f fluorescence mediated by horseradish peroxidase and H 2 O2
occui's as scopoletin concentration decreases and H2 O2  production can only be
.followed for a short time interval due to exhaustion of scopoletin. In addition, 
since direct fluorometry is required, the assay cannot be performed easily on cell 
monolayers. Some o f these problems are eliminated by using phenol red as the H- 
donor with production o f an oxidation product (Pick E, 1980). However, this 
method is relatively insensitive.
In terms o f breath condensate H 2 O2  levels, different assays and indeed different 
collection methods have been employed. This has inevitably resulted in a variety
Breath condensate was obtained as described in chapter 7.
H2O2 assay
of H 2 O 2  levels which appear to be laboratoiy specific (table 13). However, in 
general, all levels are very low and clearly a sensitive method is important. At the 
start o f this MD project, no publication had studied the intrasubject reproducibility 
o f the assay.
Breath collection
P-hydroxyphenyl acetic acid was chosen as the substrate since this method has
::::
been used for breath condensate measurements in asthmatics (Dohlman AW,
1993) and also been shown by other investigators to be the most sensitive method :for use in cell culture systems (Zaitsu K, 1980). With this method, the 
concentration o f H 2 O 2  is quantified by using a fluorometric assay based on the 
formation of an intennediate compound (compound I) from H 2 O2  by hydrogen 
peroxidase and the oxidation of p-hydroxyphenyl acetic acid (PHAA) by this 
compound to a fluorogenic compound.
H2 O2  -> compound I (transient oxidised intermediate)
PHAA -> oxidised compound (fluorogenic)
The method was first described by Hyslop and Sklar (Hyslop PA, 1984).
Fluorescence from the oxidised product was read from the excitation and emission
129
o\
O
o CN O o o o
CO
CO
rC)
p.
CO
COCO
o\
GO
CO
sscans at 310 nm and 414 mn wavelengths. Ultra violet range cuvettes were used
:
in a model LS-5B, Perkin Elmer fluorometer.
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PHAA in a 3:1 (vohvol) ratio. 1 ml of breath condensate was added to 1 ml o f the 
final PHAA and HRP mixture. 600 [x\ o f borate buffer (12.37g borate buffer in 1 1 
distilled water, adjusted to pH 10.4 with NaOH) was then added. The mixture
For the standard cuiwe, H 2 O2  stock solution was prepared from 3% H2 O2  
solution (Sigma) - O.OIM solution was first prepared by dilution with distilled 
water (1.13 ml 3% H 2 O2  and 98.87 ml distilled water), then diluted to 2 pM stock 
solution. The 2 pM solution was made fresh on the day of use. A standard cuiwe 
was prepared fiom varying proportion of 2 pM H2 O2  and distilled water, and 600 
pi borate buffer to give final concentrations of 0 to 0.73 pM.
H2O2 assay protocol
Ï
An assay used by Greening AP et al (1983) for ceil culture work was adapted for
breath condensate measurements of HgOg levels. 7.4 mg/ml p-hydroxyphenyl 
acetic (PHAA) was prepared (0.074 g in 10ml distilled water) on the day of use.
Horse radish peroxidase type II (HRP) (Sigma Aldrich) at 0.1 mg/ml was prepared 
by making lOmg/ml concentration (0.05g in 5 ml) in distilled water and diluted 
1:100 with in 2.5 % Hanks Hepes to obtain 0.1 mg/ml. HRP was then added to
was allowed to react for 1 0  minutes at room temperature in dark.
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Breath condensate was obtained from tliree CF patients (mean FEV,, 56.8%, mean 
age 19 years) and three normal subjects (mean age 28 years) for preliminaiy 
testing of this protocol.
9.3 RESULTS
The standard curve showed a good conelation coefficient (r=0.99) for 
concentrations between 0 and 0.77 uM (figure 21).
Results on three CF patients and two noimal subjects suggested discrimination at 
low levels (table 14).
It was decided that this method would be adopted for patient studies.
Î
9.4 OTHER OBSERVATIONS
Background fluorescence. At the start o f the studies it was noted that there was a 
significant amount o f fluorescence in the final mixture, when no H 2 O2  was 
present (zero o f standard curve). The cause of this was explored by changing the
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starting concentration, cuvettes, change in concentration o f HRP, age o f HRP and 
PHAA, ratio o f volume of HRP to PHAA, change in diluent for H 2 O2  stock 
solution, HRP and PHAA and changes in pH of final concentration. ;
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Figure 21. Standard curve showing fluorescence for known incremental 
concentrations of hydrogen peroxide.
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Subject H 2O2 levels in breath condensate 
(pM)
Day 1 Day 2
CFl 0.55 0.61
CF2 0.30 0.63
CF3 0.50 0.83
Normal subject 1 0 . 2 0 0.44
Normal subject 2 0.06 0 . 0
Table 14. Breath condensate hydrogen peroxide values for patients 
with CF and noimal subject on two different days.
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It was discovered in the end that the unexplained fluorescence was secondary to 
the age o f the PHAA solution. As PHAA was made up and left in the laboratory it 
is slowly oxidised in the atmosphere and this contributed to the high background 
fluorescence even without the addition o f H 2 O 2 . This was an important finding as 
a high background fluorescence contributed to the loss of sensitivity of the assay 
since the substrate (PHAA) was already partially consumed before the assay was 
used.
9.5 e f f e c t  o f  s t o r a g e  a t  -20°C o n  s a m p l e s
Methods
Using the final method, two sets of standard dilutions were made by diluting 2 
pM H 2 O 2  stock solution to obtain concentrations from 0-0.77 pM. Fluorescence 
fiom these samples were measured immediately (fresh) after addition of reactants 
and after being kept in the dark for 15 and 30 minutes. On a different day, another 
three sets o f standard dilutions were prepared. Fluorescence was then measured 
immediately, and after 24 hours, 72 hours and 7 days storage at -20°C. In addition 
5 breath condensate samples were divided into two, one measured immediately 
after collection for H 2 O 2  levels and the other stored without added reactant at - 
20°C for 5 days before being thawed and assayed.
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Results
Reacted samples are stable at room temperature in the dark for up to 30 minutes 
after addition o f reactants (PHAA and HRP) (figure 22), However with storage at 
“20°C, samples showed increasing variability and loss o f fluorescence with 
increase in storage time (figure 23). Samples kept without having had reactant 
added first showed variably decreased amounts of fluorescence compared to 
freshly assayed samples (table 15).
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Figure 22. Fluorescence of Imown concentration of H 2 O2  are maintained after 15 
and 30 minutes storage in the dark.
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Figure 23. Graph showing changes in fluorescence of known concentration of 
after storage at 20°C for 24 hours, 72 hours and 7 days.
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Sample Freshly assayed Stored for 5 days and then 
assayed
1 15 -5
2 21 8
3 15 -12
4 19 10
5 35 2
Table 15. Effect of storage in -20°C on breath condensate hydrogen peroxide levels 
from 5 normal subjects .Values in fluorescence signals.
I
9.7 REPRODUCIBILITY OF FINAL ASSAY
Methods
Results
Individual results are shown in Table 16.
134
9.6 FINAL H2O2 ASSAY PROTOCOL
A solution comprising 50 mM PHAA (Sigma-Aldrich,U.K.), 0.1 mg/ml Type 11 
horseradish peroxidase (Sigma-Aldrich,U.K) in 1:3 volume was freshly made on 
the study day. One ml of breath condensate is added to 1 ml o f this solution
within 5 minutes o f collection and a pH of 9-10 was then achieved by addition of
1 ml o f borate buffer (made to pH 10.4). The fluorescence from the oxidised
product was then read from the excitation and emission scans at 310 nm and 414
nm wavelengths perfonned in UV range cuvettes using model LS-5B, Perkin
.Elmer fluorometer. A fresh standard curve is performed each day using 3% 
hydrogen peroxide stock solution diluted in ultra heat purified distilled water.
Breath condensate was collected from five normal subjects on two different days 
( 1  week apart) and H 2 O2  assay was performed on the samples in the same fashion 
as described. Reproducibility was measured using the Bland-Altman test. 
Statistical significance was assumed at p< 0.05.
Subject H 2 O 2  levels (pM)
Day 1 Day 2
1 0.14 0.15
2 1.60 0.94
3 0.08 0.03
4 0 . 1 0 0.16
5 0 . 1 1 0 . 1 0
Table 16. Breath condensate hydrogen peroxide levels in 5 different nonnal subjects 
on 2  different days.
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9.8 DISCUSSION
9.9 CONCLUSION
H 2 O2  can be measured reproducibly in breath condensate with an assay that 
detects H 2 O2  down to 0.1 pM.
- i ' s
Bland-Altman test showed a mean difference between 2 days of 0.023 mM with a 
95% confidence interval of -0.04 to 0.08 mM
The storage of samples resulted in variable loss of fluorescence activity.
Therefore, all samples were assayed within 10 minutes of collection. It is unclear 
why this occuiTed and the finding is at variance with other investigators.
However, samples with reactants added can be kept in the dark at room 
temperature for up to 30 minutes.
4
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CHAPTER 10
HYDROGEN PEROXIDE LEVELS IN BREATH CONDENSATE OF 
CYSTIC FIBROSIS PATIENTS
10.1 INTRODUCTION
10.2 HYPOTHESIS
It was hypothesised that H 2 O2  levels in the lungs are elevated in patients with CF 
due to the increased neutrophilic inflammation and activated macrophages. This
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Lung injury in CF patients has been attributed to various factors, although basic
mechanisms have not been fully elucidated. As discussed in chapter 1.8.1,
abnormal airways secretions, decreased mucociliary clearance and loss of activity
of innate antibacterial molecules like p~defensins generate a permissive
enviromnent for bacterial colonisation and infection, driving clrronic
inflammation. The major contribution to cell damage is thought to be secondary
to proteolytic and oxidative products released by these inflammatory cells (Doring
G, 1996). The primary reactive oxygen metabolites formed in vivo are superoxide
and hydrogen peroxide, released during oxidative bursts associated with
sequestration of invading organisms. Hydrogen peroxide is also generated through
nonenzymatic and enzymatic dismutation of superoxide. Because o f their lability,
.direct detection of superoxides is difficult. H 2 O2  on the other hand is volatile,
■1
more stable and enters the gaseous phase at physiological temperatures.
may be reflected in increased levels of H 2 O2  in the condensed breath which may 
be used to follow aiiways inflammation in these patients.
Subjects and patients
Sixteen clinically stable CF patients (mean age 25.3 years, 9 males) and 14 nonnal 
subjects (mean age 29.9 years, 6  males) were recruited. Lung function in the CF 
subjects ranged from 14.8 % to 77.8% of predicted FEVi (mean FEV% : 50.2 %) 
but all were clinically stable at time of sampling (table 17). Eight o f these patients 
also had asthma, diagnosed by clinical histoiy and reversible airways obstruction 
(increase in FEVi of greater than 175 ml after 2.5 mg nebulised salbutamol) and
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10.3 STUDY DESIGN
In this study the levels o f H 2 O 2  in breath condensate of CF patients and nonnal 
healthy controls were measured and examined for correlation with lung function 
and circulating plasma leucocytes.
Expired breath condensate was collected from all subjects and assayed 
immediately for H 2 O2 . All samples were fresh and processed immediately after 
collection. Each patient contributed one (duplicate) sample. Within 2 hours of 
breath collection, FEVi was performed and venous blood was collected for 
measurement of total circulating leukocyte count and differential analysis of 
leucocytes for neutrophils, monocytes and eosinophils.
Cystic fibrosis patients Normal subjects
(n=16) (n=14)
Mean age (S.D.) (years) 25.3 (6.5) 29.9 (6.2)
Gender 9 males/7 females 6  males / 8  females
Mean FEVi (S.D.) 50.2% (20.1%) Not done
Table 17. Demographic data o f the study groups.
'1
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were on inhaled steroids. The dose of inhaled steroids ranged from 400 pg 
beclomethasone dipropionate per day to 2 0 0 0  pg fluticasone propionate per day. 
Normal subjects were healthy volunteers, with no evidence of active allergic 
rhinitis, concomitant respiratory tract infection or respiratory symptoms. For both 
groups, smokers were excluded.
Collection o f breath condensate
Breath condensate was collected using the method described in Chapter 6.3.
H2O2 assay
H 2 O 2  was assayed using the method described in Chapter 9.6.
10.4 RESULTS
H2O2 levels in breath condensate
The median level of H 2 O2  concentration in breath condensate of CF patients was 
lower than that in normal subjects (63.5 nM v 89.5 nM) but this did not reach 
statistical significance (p=0.198, Mann Whitney Rank Sum Test). There was a 
bigger range within the normal group (figure 24). Further analysis between CF 
patients on inhaled steroids and those not, showed no difference in mean levels
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Figure 24. Breath condensate levels of hydrogen peroxide in patients with CF 
compared to nonnal subjects.
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Relationship of H2O2 levels and lung function
Within the CF group, there was no significant correlation between H 2 O2  level and 
lung flinction, although the trend is for higher levels of H 2 O2  in better patients (r= 
“0.20, p=0.55 ) (figure 25).
Relationship o f H2O2 levels and circulating inflammatory cells
There was a modest but insignificant positive coiTelation between H 2 O2  and 
circulating leucocytes and neutrophils (figure 26).
10.5 DISCUSSION
inhaled steroids, n= 8 ; 68.4 nM) 3#'-3'
It has been shown previously that activated human macrophages release a large 
amounts of H 2 O2  extracellularly (Greening AP, 1983). Even larger amounts of 
H 2 O 2  are released from neutrophils (Shult PA, 1985) and H 2 O 2  release has been 
measured from apical surfaces of tracheal epithelial cells, monocytes, rat alveolar 
type II cells and eosinophils (Kinnula VL, 1992a&b). The levels that we have 
observed in the CF patients (range of 0.04 to 0.11 pM) were below the range 
reported previously by other groups working in stable asthmatic children (mean of
0.54 pM and median of 0.6 pM from two different authors) (Jobsis Q, 1997.
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Figure 25. Relationship between breath condensate levels and lung function in 
patients with CF.
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Figure 26. Relationship between breath condensate H2 O2  and peripheral total 
leucocyte and neutrophil count.
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Dohlman AW, 1993) and stable COPD (0.12-0.55 |aM) (Dekhuijzen PNR, 1996).
All the normal ranges, however, were similar to ours : 0-0.8, 0-0.1 and 0.08-0.23 
\xM compared to our levels of 0.008-0.15 pM.
In experimental animals, lung injuiy caused by complement activation can be 
attenuated by superoxide dismutase, catalase and desferrioxamine (Seekamp A, 
1993. Ward PA, 1983). All are antioxidants which scavenges the free radicals 
released by these cells. In ARDS, where neutrophil accumulation and stimulation
is thought to amplify lung damage, glutathione levels, a major antioxidant in the 
.airway epithelial fluid lining has been found to be decreased (Pacht ER, 1991) 
and H 2 O2  in the exhaled air of intubated patients elevated (Baldwin SR, 1986. 
Kietzmann D, 1993). Thus in CF, where neutrophilic inflammation predominates 
and alveolar macrophages are thought to be constantly stimulated by bacterial 
colonisation, it was expected that hydrogen peroxide generation would be high 
and that this might be detected in expired breath. In this study I have found no 
elevation of H 2 O2  in very inflamed airways. This is the case, even in the patients 
with concomitant astlima, although inlialed steroids may have been a confounding 
factor.
There are several possible explanations for this. In the context of the general 
investigation o f this MD project, it is possible that hydrogen peroxide is generated 
but not detectable due to rapid reaction with other reactive species - superoxide, a 
source of extracellular H 2 O 2  is Icnown to react rapidly with the free radical NO to 
form peroxynitrite. The other possibility is that with large amount o f viscous
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secretions within the airways, volatile substances like H2 O2  are prevented from 
diffusing into the airway lumen. This is supported by the small range of H2 O2
levels within our CF group - suggesting that whether the levels were high or low,
factor comes from the modest correlation between H 2 O2  in breath condensate and 
circulating leukocyte count. This suggests that there may be a correlation with 
inflammatory burden but that this was not detectable in the expired breath.
only a certain amount was able to escape into the lumen. Another supporting
An alternative explanation may be that there is an increase in the release, by 
neutrophils and monocytes within the CF enviromnent, of myeloperoxidase or an 
antioxidant like catalase (Worlitzsch D, 1998). The fonner generates hypohalous 
acids in the presence o f H 2 O2  and halides, thus effectively removing H 2 O2 . Both 
catalase and MPO are positively charged while the airway secretions are 
negatively charged (due to excess DNA from degraded inflammatory cells). They 
may therefore be “trapped” for a longer time in this enviromnent. If the residence 
time of catalase is indeed increased, then it could be suggested that aiiivays 
secretions in CF may be protective against further inflammatory cell injury. There 
is some evidence suggesting the protective nature of airways secretions in CF- 
preliminaiy in vitro studies have shown increase in levels o f free IL 8 , a peptide 
with affinity for the anionic DNA, with the addition of recombinant DNA-ase to ;;
sputum in vitro (Perks B, 1997).
'I
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10.6 CONCLUSION
These results, taken together with the findings on exhaled NO and nitrite suggest 
that the lack of elevation o f NO in the exhaled air is likely to be secondary to 
decreased detection of gaseous molecules in cystic fibrosis rather than decreased 
in production. It is unlikely that decreased levels of two reactive gaseous products 
are attributed to lack of production in the face of overwhelming in vitro evidence 
for increase in its production.
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SUMMARY OF THESIS FINDINGS
1. Gaseous NO can be measured reproducibly in the exhaled air of normal
CHAPTER 11
11
The thesis concludes that
t
subjects. With my method, the 95% confidence interval for any measurement 
o f NO is ±1.72 ppb.
2. Using the method o f detection as in this project, increased levels of ambient 
NO does not affect measurement of endogenous NO from the airways.
3. Exhaled nitric oxide is not increased in patients with cystic fibrosis in contrast 
to asthmatics, in spite of airways inflammation and acute infective 
exacerbation.
4. There is a significant positive correlation between exhaled NO levels and FEV, 
in CF patients.
5. Exhaled NO is not elevated in bronchiectatic subjects compared to normal 
subjects and in contrast to asthmatics.
6 . Exhaled hydrogen peroxide can be measured in the breath condensate of CF
and normal subjects.
7. Hydrogen peroxide levels are not increased in CF patients compared to noimal 
subjects.
8 . Nitrite, a stable end product of nitric oxide can be assayed reliably in breath 
condensate.
Î
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9. Breath condensate nitrite levels in CF subjects are increased compared to 
normals, in contrast to exhaled NO levels. This suggests that NO production in 
airways o f CF subjects is increased. The cellular source o f this NO is unknown. 
lO.In these patients, there is a significant positive correlation between condensate 
nitrite levels and circulating leucocytes and neutrophil counts but not with 
FEV,.
11.NOS II gene is expressed in both primary nasal epithelial cells and epithelial 
cell line (ECFTE) of CF patients and respond nonnally to proinflammatory 
stimuli. The presence of CFTR mutation does not affect NOS II expression in 
epithelial cells.
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CHAPTER 12
OVERALL DISCUSSION AND CONCLUSION OF THESIS
The finding of low levels of exhaled NO in cystic fibrosis patients stimulated me 
to examine the reasons for this. This was important because if, indeed, NO
145
This thesis has explored issues pertaining to a newly available methodology for 
measuring exhaled NO levels, reported new findings on NO production in the 
airways of patients with CF and bronchiectasis and developed new methods for 
detecting NO production in the lower aiiivays. It has also raised questions about 
the interpretation o f exhaled NO levels and our ability to measure endogenous NO 
production in chronically inflamed airways.
The first part o f the thesis validated a new method for measuring NO levels in the 
exhaled breath. This was an important part o f the thesis as subsequent studies and 
conclusions depended on a reproducible and accurate method o f measuring 
aii*way NO. I determined a consistent point of measurement on the exhalation 
profile and found that this was not affected by inspired NO levels. Also, it was 
found that mouth pressure and therefore, exhalation rate affected the end
■
expiratory NO levels. An important factor for accurate measurement was the 
ability to exclude contribution of nasal or paranasal NO to lower airway NO. I was 
able to do this with an analyser which had a novel built-in mechanism that 
prevented mixing of nasal and lower airway air.
production was low, then this could potentially contribute to decreased bacterial 
resistance in CF airways. It was also possible that the presence o f the CFTR 
mutation may have contributed to a defect in expression of the NOS II gene.
Putting all my findings together, it appears most likely that exhaled NO levels in 
CF are reduced because of a defect in detection rather than total production of NO 
in the airways. This is suggested by the finding of elevated levels o f breath 
condensate nitrite in contrast to NO in gaseous form. The anomaly in detection 
may occur because although exhaled NO appears an easy method of measuring 
NO production in the airways, it suffers fiom a few limitations. Firstly it requires 
NO to be in the gaseous phase and in the presence of excess secretions, the gas is 
impeded from diffusing into the exhaled air. Secondly within severely inflamed 
environments, gaseous NO reacts quickly with other reactive molecules (not 
usually present in noimal airways) to form other products. These factors are most 
relevant to chronic suppurative states like CF and bronchiectasis.
It can be argued that similar reactions could occur in asthmatics because these 
patients also have increased levels of reactive molecules in their airways. 
However, two points ought to be borne in mind with exhaled NO levels in 
asthmatics in this regard. Firstly, not all asthmatics have increased levels of 
exhaled NO and the reason for this is still unclear. My study in chapter 3 showed 
that exhaled NO levels in asthmatics ranged between 2.2 and 52 ppb. The large 
range in NO levels may be secondaiy to varying amounts of reactive species in 
the airways. Secondly, the cause of increased NO levels in asthmatics is still
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uncertain. There is evidence to suggest that exhaled NO levels do not bear any 
relationship to clinical severity or lung function in astlunatics (Ho LP, 1998. ten 
Hacken NHT, 1997). Its levels may bear a closer relationship to eosinophilic 
inflammation rather than neutrophil influx as seen in CF (Jatakanon A, 1998). 
Therefore, comparison of inflammation in general between these two disease 
processes may be inappropriate. Indeed, airways inflammation is a heterogeneous 
entity. Hence in cystic fibrosis this is characterised by an infection driven process 
and the cytokine pattern is dominated by IL6 , IL 8  and TNFa with neutrophils 
being the predominant inflammatory cells. In contrast, asthmatic inflammation is 
mediated in main by leukotriene (especially LTD4), IL4, IL5 and IL13, with 
major inflammatory cells being the eosinophils, mast cells and CD4+ T cells (Tak 
HL, 1998).
At present, the relationship of exhaled NO (as opposed to NO production) with 
inflamed airways is still under debate. NO levels are not elevated in conditions 
like ARDS which is characterised by overwhelming sequestration o f neutrophils 
in pulmonary extravascular tissues. My studies on CF have contributed to the 
debate on the interpretation o f increased exhaled levels of NO in inflammatory 
airway conditions and suggested that elevated NO levels do not necessarily equate 
to inflammatory activity in the airways. This is partly because the tool we have for 
measuring NO production is imperfect, contributed in part by the highly reactive 
nature o f gaseous NO.
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It is also possible to speculate that increased exhaled NO levels are umelated to 
neutrophil or eosinophilic inflammation; instead, they may be an allergen-induced 
phenomenon and secondary to upregulation of NOS II expression in epithelial 
cells, mast cells or antigen presenting cells (e.g. macrophages), on contact with 
airborne allergen. This will be in keeping with data showing a positive coiTelation 
between exhaled NO levels and bronchial hyperresponsiveness in animals and 
humans (Dupont LJ, 1998. Persson MG, 1993). Further, exhaled NO levels are 
also increased in asthmatics who are atopic, some normal atopic subjects and 
some with allergic rhinitis (Martin U, 1996) The determination of enzymatic and 
cellular sources o f NO detected in the exhaled breath is a cuiTent challenge in NO 
research. The answer to this question is unlikely to be derived solely horn human 
studies and work on NOS knockout animals are likely to be more productive and 
conclusive.
The thesis highlighted another potentially important finding. Taken together with 
Polak’s study (Meng Q-H, 1998) where NOS II expression was found to be absent 
in bronchial epithelia o f end stage CF patients, my finding of low exhaled NO 
levels but preserved NOS II expression in the epithelial cells of CF may mean that 
epithelial NO production in chronically inflamed lower airways may be decreased. 
However, NOS II expression in inflammatory cells in CF is nonnal and this is the 
likely reason for the increased nitrite levels that I found in breath condensate of 
these patients. This implies that chronic inflammatory stimuli or persistent NO 
production may downregulate the expression of NOS II in epithelia. NO 
production is persistently provided by ‘freshly’ infiltrated inflammatory cells. This
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,makes sense physiologically as very high levels of NO would be detrimental to a
biological system and a mechanism to switch this off should be in place to prevent 
injurious effect. A few studies have reported autoinhibitory effects o f high NO on 
its production (see chapter 1.6.3). Therefore, if  there was persistent migration of 
new neutrophils to the airways with accompanying high NO generation from these 
cells, then it can be envisaged that epithelial NO production might be switched 
off. This may be inappropriate if the there remains a need for NOS II activity.
The contribution of epithelial NO production to host defence is unknown.
;■
Traditionally, the airway epithelium has been regarded as a relatively passive 
physical barrier to invasion of foreign organisms. However, its role in host 
defence has become more prominent in the recent years. It is able to exert active 
effects by producing chemicals with anti-microbial activity like p defensins and 
the CFTR protein itself may aid ingestion of bacteria. It can be envisaged that 
epithelial NO may contribute actively to the function of the epithelium in host
s.;
defence. NO is also likely to have an effect on ciliaiy activity and therefore, low 
or absent epithelial NO production may affect mucociliary clearance. Recent 
studies have also demonstrated that there is 'constitutive' expression of NOS II in 
airway epithelia (Guo HF, 1995). Whether this is truly 'constitutive' and 
unprovoked or whether the samples are representative of atopic, mildly stimulated 
epithelium (e.g. by airborne allergen) is still unknown. However, if it is true that 
normal airway epithelia express NOS II, then it means that there is constant 
background requirement for high level NO production and the loss is 
inappropriate, especially during chronic infective states. It is also known that NO
is involved in the modulation of T helper (Th) lymphocyte differentiation, 
causing polarisation to a Th2 subset (Huang FP, 1998 ). This T cell subset is 
characterised by production of IL4, IL5 and IL13, cytokines which promote 
humoral and allergic response in contrast to IFNy, IL2 and TNFa produced by 
Till subset which promote cellular immunity. Conceivably, different levels of NO 
may influence the Th cell differentiation and hence the associated type of 
inflammation.
My studies of nitrite and hydrogen peroxide levels in condensed breath had a dual 
purpose o f aiding the understanding of why exhaled NO levels were not elevated 
in CF and examining two other possible methods of non invasively monitoring 
airway inflammation. In teims of the latter, breath condensate hydrogen peroxide 
was not found to be useful as the levels were very low in both noimal and cystic 
fibrosis patients. Realistically the discriminatoiy power of such low levels is poor 
and although longitudinal studies are needed to determine that they remain low 
during infective episodes, it appears unlikely that this method will prove useful.
Nitrite levels however, showed widely differing levels within the patient group 
and also between patients and nomials. Encouragingly, the levels also coirelated 
with peripheral circulating leukocytes. The assay is easily and quickly performed 
on microplates, making the method viable in the context of a clinical trial. This 
method offers an alternative to the use of induced sputum as a non invasive 
method of sampling airway inflammatory activity. Induced sputum, although non 
invasive, has a few drawbacks ~ it is not possible to gauge the relative
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contribution o f different parts of the airways to the final sputum collection, nor 
how long the sputum has been present in the aiiways. In addition, there is a small 
risk o f inducing severe bronchospasm with hypertonic saline. Breath condensate 
measurements, on the other hand, allow instantaneous sampling of inflammatory 
events at the time of measurement. They also sample the airways ‘globally’ thus 
representing net inflammation within the lungs.
The studies on breath condensate studies have also highlighted areas that need 
further development. The present system of breath collection involves 
condensation of exhaled breath within a coiled Teflon tube immersed in ice. The 
method poses two major limitations: a) the requirement for constant supply o f wet 
ice, thus limiting its ‘portability’ and practicality in large studies and clinics and 
b) inability to store collected samples. This may be secondary to presence of other 
inhibitors or molecules within the breath sample/condensate which react with the 
molecule o f interest. Two important improvements to the assay would be the 
ability to collect samples quickly and to store these indefinitely. Recent reports 
have suggested that freeze drying breath condensate samples may provide a 
reliable method of storage and this may be a way forward for this assay,
LESSONS FROM  THE PR O JEC T
With the benefit o f hindsight, there are a few things that I would have done 
differently if  I were to do the project again. It would have been much more 
interesting and profitable to have concentrated on two strands of finding - that of
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high nitrite production in breath condensate and that of low NOS II expression in 
epithelial CF cells. The studies I have performed have, in large, been cross
152
sectional studies. Although these were necessaiy to detect differences from the 
normal population, I would have followed the lead from these studies and 
examined reasons for the abnoraialities detected. Hence, in the exhaled nitrite
:
studies, I would have selected a group of patients who were not on inhaled 
steroids and followed the course o f breath condensate nitrite levels longitudinally.
Knowledge o f day to day baseline variation in NO levels within CF patients and 
the effect o f exacerbation and treatment would have provided important 
infonnation on its potential use in clinical practice.
With regards to the studies on NOS II gene expression, I would have included 
patients with bronchiectasis in the study. This would have given me more
.i
information on the effect o f chronic inflammation on NOS II expression. The use 
o f nasal epithelium was necessary because of ethical considerations but this 
clearly limited my conclusions on activities of the NOS II gene in the lower 
aimay. In retrospect, I would have obtained bronchial epithelial cells fi’oni CF 
explanted lungs and concentrated on culturing these cells and examining NOS II 
expression at baseline, to proinflammatory cytokines and to prolonged 
inflammatoiy stimulus. This would be compared to cells obtained by 
bronchoscopic bmshings of normal bronchi h'om subjects undergoing diagnostic 
bronchoscopy who subsequently turn out not to have active disease.
.One other experiment I would have done in the nasal epithelial cell studies would 
have been to stimulate the cells with cytokines and LPS for longer than 24 hours.
It was originally thought that since cells removed fi'om the bronchus show a 
natural loss in NOS II expression after 8  hours, experiments performed longer 
than that would be confounded by this factor. Therefore, experiments were limited
:
to 24 hours. However, with hindsight, a control well (with no stimulus), to show
'change o f gene expression over time could have been included. I would also have 
looked at the effect of excess NO, by incubating the cells with NO donors, and the
effect o f IL 8 , on NOS II expression. ■1
Further, I would have measured the levels o f nasal nitric oxide simultaneously 
with obtaining nasal cells. This would have helped detennine if the levels of NO 
produced in the nose correlated with epithelial NOS II expression.
FUTURE DIRECTIONS
The project has highlighted the question of the source of NO detected in the 
exhaled breath. It is not clear whether NO levels originated mainly from NOS II or 
other NOS’s or indeed, if  levels are NOS II derived, whether this is NOS II from 
the inflamed epithelia or inflammatory cell influx. The answer to this question is 
unlikely to be derived fully fiom human studies and work on animal models are 
likely to be more productive and conclusive. Recently NOS I, II and III knockout 
transgenic mice have been generated. Direct comparisons o f NO levels in the
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exhaled air of these animals and the consequent effect of these levels on bronchial 
hyperresponsiveness would add substantially to available human data.
Still linked with host defence but from a different perspective, is the effect of NO
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The relationship between NO and other inflammatory mediators and transcription 
factors such as NF-KB and the effect of oxidative stress on transcription in 
chronic inflammation may provide some answers to the cause of down regulation 
of NOS II expression. However, it will be important first to substantiate the 
finding that epithelial NOS II is indeed decreased in chronic inflammatory states 
and second to examine if this decrease affects host defence, specifically if 
bacterial colonisation, infection and adherence to cilia is decreased. The CF 
transgenic mouse with chronic pulmonaiy bacterial infection is likely to provide a 
good model for examination of the effects of clironic inflammation on NO 
production and recurrent bacterial infection in vivo. Until these studies are
performed, the implication of low NO levels on host defence remains speculative.
on ciliary motility. It has been demonstrated that nasal NO is low in CF patients
and also in Kartegener’s disease. There are preliminary reports which showed that 
.patients with primary ciliary dyskinesia also have very low levels o f nasal NO.
These data suggest that NO may be involved in the signaling pathway for ciliary 
. .activity. Apart from the possibility of using nasal NO levels as a diagnostic test
for primary ciliary dyskinesia, exploration of this area could also lead to 
mechanisms of restoring appropriate NO levels and improvement of ciliary 
motility in these patients.
■fI
a"O';Outwith the area o f cystic fibrosis, exhaled NO research is moving into studies on
the utility of exhaled NO levels in clinical practice, particularly in relatively more
common conditions like COPD. Potentially, exhaled NO levels could be used as a
.sensitive marker of disease deterioration and predictor of corticosteroids
requirement. This would greatly enhance clinical practice and management of 
respiratory diseases like COPD and asthma. In this sense, long temi longitudinal
whether this increase is actually ‘protective’ - i.e. is the increase secondary to
overcome bronchoconstriction? This is pertinent since there are studies which
studies will be needed together with studies on the effect of natural history of the 
disease on NO levels. This thesis has shown that exhaled NO levels vary widely in 
asthmatic patients and a large proportion of steroid-fi'ee the patients have normal 
levels. The reason for this is unclear. There is still some way to go in 
understanding the biological role of NO in asthma and the implications of 
increased levels of exhaled NO before its use in clinical practice becomes a 
reliable possibility.
..'t
In recent years, large community studies on the effect of atopy on NO have also 
emerged, showing that atopic children have higher levels o f NO compared to 
normal children. The logical next step in these studies will be to examine if
increased levels of NO in these children are a predictor of development o f astlima. 
In teims of understanding basic mechanism, it will be interesting to determine
upregulation o f the NOS 1 gene in bronchial epithelium and iNANC pathways to
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suggest that low levels of NO (in the form of s-nitrosotliiols) may be responsible 
for a more severe outcome in asthmatic exacerbation.
CONCLUSION
In summaiy, this thesis has reported that exhaled NO measurement is 
reproducible but levels in the exhaled air may not necessarily reflect total NO 
production. I have shown that exhaled NO levels in CF and bronchiectasis are not 
increased but breath condensate nitrite levels are (in CF). These data suggest that 
Tow’ levels are likely to reflect lack of detection rather than decreased production 
from the lower airways. The thesis highlights the point that there remains no clear 
information as to the major enzymatic, cellular and anatomical sources o f NO 
detected in the exhaled breath. We are also uncertain about what proportion of 
total NO production is reflected by exhaled gaseous NO since a large proportion 
could theoretically have reacted close to its site of production. All this infonnation 
is important to the basic understanding of the role of NO in pathological processes 
and development o f strategies to address the abnormalities in production. The 
possibility o f downregulation of epithelial NOS II due to chronic inflammation 
rather than abnonnal expression secondary to CFTR mutation is suggested by 
normal response in cell lines and primary cell culture to proinflammatory stimuli 
together with findings from Polak’s group that NOS II expression is markedly 
reduced in end stage CF bronchial epithelium.
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